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Antioxidants vitamins, such as A, C and E, play a crucial role in maintaining health. 
Research showed that antioxidant vitamins, particularly vitamin C, are essential for 
scavenging of superoxide and other reactive oxygen species and moreover, protect 
against certain diseases. Recently, extensive evidence showed that high levels of 
sulfur-containing amino acids are associated with coronary heart disease, liver 
cirrhosis, as well as Alzheimer's disease and renal disorders. Sulfur-containing 
amino acids are believed to be harmful to our health by inducing oxidative damage. 
However, whether this oxidation processes caused by sulfur-containing amino acids 
decrease the levels of antioxidants, such as vitamin C, in our body remains unknown. 
In the present study, the effects of sulfur-containing amino acids, including 
homocysteine, cysteine, methionine and taurine, on ascorbic acid status and the 
mechanisms involved were investigated in male BALB/c mice, /^-cysteine was 
included to determine if stereospecificity exists. In order to determine whether the 
changes on ascorbic acid status were limited to sulfur-containing amino acids, leucine, 
which serves as a non-sulfur-containing amino acid control, was also investigated. 
In -the present study, we observed that i.p. administration of 100 mg/kg/d of 
sulfur-containing amino acids modified ascorbic acid concentrations in the plasma 
and tissues, including the kidney, liver and brain. Our results showed that 1-week 
administration of methionine, homocysteine,丄-cysteine significantly decreased 
ascorbic acid concentrations in the plasma, kidney and liver. In the brain, the 
ascorbic acid concentration was significantly increased after homocysteine,丄-cysteine 
and taurine treatment, while a significant decrease was observed in the methionine 
group. In contrast, no significant changes were observed in the heart throughout the 
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experiments. These findings suggest that the modifications in ascorbic acid levels 
by sulfur-containing amino acids are tissue/organ specific. Our results also indicated 
that I-cysteine and D-cysteine had different effects on vitamin C distribution in mice. 
This phenomenon suggests stereospecificity exists. Furthermore, we found that 
1-week administration of leucine resulted in a significant decrease in ascorbic acid 
concentrations in the kidney, liver and brain, while no significant changes were 
observed in the plasma and heart. These indicate that the effects on the changes in 
ascorbic acid status are not only limited to sulfur-containing amino acids. In 
addition, a significant decrease in ascorbic acid status in the kidney and liver was 
observed after 1 day and 14 days treatment with sulfur-containing amino acids and 
leucine. These suggest that both sulfur-containing amino acids and leucine have 
significant effects on vitamin C levels in a relatively shorter and longer treatment 
period. ' 
Cellular ascorbic acid accumulation occurs through two facilitated transport 
mechanisms: either by direct uptake of ascorbic acid through sodium-dependent 
vitamin C transport proteins (SVCT), or by uptake of dehydroascorbic acid via 
glucose transporters (GLUT) and followed by intracellular reduction to ascorbic acid. 
In the present study, we focused on determining the effects of sulfur-containing amino 
acids and leucine on the gene expressions of SVCTl, SVCT2 and GLUT3 in various 
tissues. 
Molecular studies indicated that the changes in ascorbic acid status are related to the 
changes in the levels of SVCT and GLUT3 gene expressions in tissues. Our results 
demonstrated a reduction in ascorbic acid concentrations and SVCT mRNA levels 
after receiving methionine, homocysteine,丄-cysteine and leucine for 7 days in both 
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kidney and liver. Besides, a decrease in the ascorbic acid concentrations and SVCT2 
mRNA levels was found in the brain of the leucine group. These results suggest that 
a decline in the sodium-dependent ascorbic acid transport may account for the loss in 
tissues ascorbic acid content. 
In the brain，ascorbic acid concentration was increased significantly following 7-day 
administration of homocysteine and L-cysteine. An increase in GLUT3 mRNA 
levels was observed, while no significant changes in SVCT2 mRNA levels were 
found. The above results suggest that an increase in GLUT3 levels may 
consequently lead to an increase in the brain ascorbic acid levels. 
In order to establish if there were any correlations between the levels of 
sulfur-containing amino acids, leucine and the changes of ascorbic acid status, the 
sulfur-containing amino acids and leucine concentrations in the plasma were 
determined with an amino acid analyzer. Our results showed that in general there 
were no significant changes in the levels of methionine, cystine, taurine and leucine 
after 7 days treatments. Following 14 days administration of methionine, 
homocysteine, L-cysteine and leucine, a significant decline in cystine concentrations 
were observed. Besides, the methionine concentration in the leucine group was 
lower than that in the control group. A significant decrease in leucine concentrations 
were also found after administration of homocysteine, cysteine and leucine. The 
above results suggest that the changes in amino acid concentrations in the plasma 
exist in a relatively longer treatment period and no clear correlation between the 
levels of sulfur-containing amino acids, leucine and the changes of ascorbic acid 
status is observed. 
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In summary, our results suggest that i.p. administration of high concentrations of 
sulfur-containing amino acids modifies ascorbic acid concentrations in the plasma and 
tissues, and one of the mechanisms involved is by altering the expression of ascorbate 
transporters. 
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摘要 
抗氧化維生素’例如：維生素A、C ’ E，在維持健康狀況中扮演著重要的角 
色。硏究報告指出抗氧化維生素’尤其是維生素C ’在清除超氧化物及其他對氧 
易反應的物質中是不可缺少的。此外，維生素C還能有效地防禦疾病0最近大 
量證據顯示’血中硫擴氨基酸(sulfur-containing amino acids)濃度過高和冠狀動脈 
心臟病、肝硬化、阿爾兹海默氏病及賢臟失調有密切關係0硫磺氣基酸危害健 
康相信是氧化損害所導致的。然而，硫磺氛基酸所產生的氧化作用是否減少體內 
之抗氧化劑濃度，例如：維生素C，仍是未知。在本硏究中’我們用雄性BALB/C 
小鼠來硏究硫磺氨基酸，包括：同胱氨酸(homocysteine)�半胱氣酸(cysteine)� 
蛋氣酸(methionine)和牛磺酸(taurine)對維生素C濃度的影響及其機制。爲測定立 
體結構選舉性(stereospecificity)是否存在，/)-半胱氨酸也在硏究之列°此外’我 
們更選擇了白氣酸(leucine)充當非硫磺氣基酸對照物來確定對維生素C狀況的影 
響是否只限制於硫磺氣基酸。 
我們的實驗結果顯示，在腹腔內注射硫磺氣基酸(100毫克/日)能改變血漿、腎臟、 
肝臟及腦內之維生素C濃度。經過爲期一週的蛋氣酸、同胱氨酸和型半胱氛 
酸的注射後，血漿、腎臟及肝臟內的維生素C含量明顯地降低°此外，在接受 
同胱氨酸、Z-半胱氣酸及牛擴酸後，它們顯著地提升了腦內的維生素C濃度，而 
在接受蛋氨酸的組別之腦內維生素C濃度則顯著下降。然而，在心臟內的維生 
n C含量並無顯著改變。這表明硫磺氣基酸對維生素C更改之現象是組織特異 
性的（tissue/organ s p e c i f i c ) �我們也發現半胱氣酸及半胱氣酸對維生素C有 
不同的影響。由此可見，立體結構選寧性是存在的。再者，我們觀察到在注射白 
氣酸一週後，於賢臟、肝臟及腦內的維生素C濃度顯著地下降。這指出對維生 
素（；：狀況的影響不只限制於含硫磺的氣基酸。此外，我們也注意到在注射硫磺 
氣基酸和白氛酸一日及十四日後，腎臟及肝臟內的維生素C含量明顯地降低。 
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這表明較短和較長的硫磺氨基酸及白氣酸之療程對維生素C濃度也有重要的影 
響。 
細胞中維生素C的積聚可通過兩種輔助型運輸(facilitated transport)之機制：直接 
地通過依賴鈉離子維生素C運輸性蛋白質(sodium-dependent vitamin C transport 
protein; SVCT)攝取抗壞血酸(ascorbic add)或經由葡萄糖轉送體 (g lucose 
transporters; GLUT)攝取去氫抗壞血酸(dehydroascorbic acid)，隨後在細胞內還原 
爲抗壞血酸。在本硏究中，我們會集中硏究含硫磺氣基酸及白氨酸對不同組織中 
的SVCT1，SVCT2和GLUT3基因表達之影響。 
分子硏究顯示維生素C含量的變化和SVCT及GLUT3基因表達程度有密切的關 
係。我們的實驗結果顯示，在注射蛋氣酸、同胱氣酸、//半胱氣酸及白氣酸一週 
後，腎臟和肝臟之維生素C濃度及SVCT的信息核糖核酸(mRNA)程度顯著地下 
降。此外，在接受白氨酸的實驗組別中，腦內的維生素C濃度及SVCT的信息核 
糖核酸程度也同樣減少。從上述結果看來，維生素C含量的減低與依賴鈉離子 
維生素C運輸性蛋白質之下降是相關的。 
在注射同腕氨酸及"半胱氨酸一週後，腦內的維生素C濃度顯著地增加0我們 
也觀察到GLUT3的信息核糖核酸上升，而SVCT2之基因表達則無顯著改變。這 
些結果表明由同胱氨酸及L-半胱氨酸所誘發的維生素C濃度提升可能是通過它 
們對GLUT3基因表達的增加。 
爲確定含硫磺氨基酸和白氨酸之濃度與維生素C的改變是否有關，我們使用氛 
基酸分析器來測定血槳的硫磺氨基酸和白氣酸之含量。我們的結果指出，一般 
地’經過一週的藥物注射後，血槳內的蛋氨酸、胱氣酸(cystine)�牛磺酸和白氣 
酸並無顯著改變。在注射蛋氨酸、同胱氨酸、半胱氨酸及白氨酸十四天後’腕 
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氣酸濃度顯著地下降。此外，我們也觀察到在接受白氨酸組別中的蛋氨酸濃度比 
對照物的爲低。再者，在注射同胱氣酸、半胱氣酸及白氨酸後，白氨酸濃度也相 
繼降低。從上述結果，我們看到血漿內氣基酸的改變出現在較長的療程中，但未 
能在硫磺氣基酸和白氨酸之濃度與維生素C的改變之間觀察到一個清晰的相互 
關係。 
總括而言，是次硏究提出在腹腔內注射高濃度的含硫磺氨基酸及白氨酸能改變血 
獎和組織內之維生素C濃度，而改變維生素C運輸性蛋白質(ascorbate transporters) 
乃其一機制。 
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CHAPTER 1 INTRODUCTION 
1.1. Sulfur-Containing Amino Acids 
In 1915, Osborne and Mendel observed that addition of cystine to a low-casein diet 
restored rapid growth of rats (Martha, 1999), and the importance of sulfur-containing 
amino acids for growth or protein synthesis was suggested. Later, methionine was 
also shown to be an effective supplement to the low-casein diet (Martha, 1999). 
Further studies showed that dietary methionine was sufficient, while cyst(e)ine was 
not essential for rats (Martha, 1999). At present, methionine is considered as an 
essential amino acid and it must be obtained from the diet. The dietary sources of 
methionine include fish and other seafoods, meat, poultry, sesame seed and cottage 
cheese. ‘ 
The importance of methionine for growth has attracted attention to other 
sulfur-containing amino acids. Homocysteine was discovered by Du Vigneaud in 
1932' as the product of methionine demethylation. It is an intermediate in the 
conversion of methionine to cysteine. Recently, the clinical significance of 
homocysteine has been recognized. Studies showed that elevated plasma 
homocysteine (hyperhomocysteinemia) was associated with cardiovascular disease 
(Cattaneo, 1999; Refsum et al., 1998), end-stage renal disease (Bostom et al., 1997; 
Dennis et al., 1996)，and cognitive dysfunction including Alzheimer's disease (Clarke 
et al, 1998; Lehmann et al., 1999). 
More recently, the nutritional importance of taurine, an end-product of cysteine 
catabolism, has been established. Taurine is widely distributed in animal tissues and 
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has a variety of physiological and pharmacological functions (Huxtable, 1992; Wright 
et al., 1986). Epidemiological studies suggest that taurine intake is beneficial for 
preventing cardiovascular disease (Yamori et al., 1987), for examples. Taurine also 
participates in lipid metabolism in the conjugation of bile acids (Jacobsen et al., 
1968). 
The structures of homocysteine, cysteine and taurine and their relations with their 
common precursor, methionine, are shown in Fig. 1.1. They have an asymmetric 
carbon atom; and the L-isomers of methionine, homocysteine, and cysteine are the 
biologically active forms. The carbon skeleton of homocysteine has one more 
carbon than that of cysteine. Taurine is formed from cysteine by removal of the 
carboxyl group and oxidation of the sulfur to form a sulfonic acid group. 
NH, 
Methionine CH 厂 S-CH^-CHj- CH- COO 
I NKj 
Homocysteine HS-CH 广 CH 广 tn-CXX? 
serine 
NH^  、， NH3 
Cystathionine OOC-CH-CH.-S — CH,-CH,-CH-COO 
‘ + fl-ketot)glyrate + NH 嫂 
NH-> 
- I ‘ V 
Cysteine OOC-CH-CHj-SH 
. �i 
NH3 j 
Taurine CHj— CHj 一 SOj 
Fig. 1.1 Structures and metabolic relations of sulfur-containing amino acid 
(Modified from Martha, 1999) 
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1.2. Metabolism of Sulfur-Containing Amino Acids 
Methionine generates one-carbon methyl group for many transmethylation reactions 
which are essential to all life forms and homocysteine is an important intermediate in 
the methionine cycle (see below). In mammals, homocysteine can be diverted from 
the methionine cycle into the transsulfuration pathway to produce cysteine, a 
nonessential amino acid. Cysteine acts as a precursor for protein synthesis and 
several essential molecules, including, glutathione (GSH), coenzyme A, taurine, and 
inorganic sulfur. The essential amino acid methionine, therefore, is the precursor of 
homocysteine and cysteine. The metabolic pathway is summarized in Fig. 1.2. 
1.2.1. The Metabolic Pathways 
Methionine metabolism in mammalian cells has two major reaction sequences: the 
methionine cycle and the transsulfuration pathway. 
Methionine Cycle 
The methionine cycle presents in all normal mammalian cells (Finkelstein, 1990). 
Cells have the ability to synthesize S-adenosylmethionine (AdoMet) (Reaction 1, Fig. 
1.2); however, only liver has the high Km methionine adenosyltransferase III that 
allows increased AdoMet synthesis in response to excessive methionine. AdoMet 
serves as the methyl donor in many transmethylation reactions (Reaction 2, Fig. 1.2). 
On the other hand, following decarboxylation (Reaction 9, Fig. 1.2), the propylamine 
moiety can be used in the sequential syntheses of the polyamines. After 
propylamine transfer, 5 -methyIthioadenosine can be recycled to form methionine 
(Backlund etal., 1981). 
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In the AdoMet-dependent transmethylation reactions, AdoMet generates 
5-adenosylhomocysteine (AdoHcy), which is a potent inhibitor of methyltransferase 
enzymes (Cantoni et al., 1978). To allow metabolism to proceed, AdoHcy is 
removed or metabolized by one of the three processes. Firstly, AdoHcy may be 
transported to the extracellular space from which it can be removed primarily by the 
kidney (Duerre et al.，1969; Hoffman et al., 1979). Secondly, it can be bound by 
specific, saturable, intracellular sites. Svardal et al. (1987) demonstrated 30-50 % of 
AdoHcy in rat liver and isolated rat hapatocytes is associated with proteins. Under 
physiological conditions, the major fraction of protein-bound AdoHcy resides in the 
microsomal fraction, whereas most free AdoHcy was recovered in the cytosol. 
Thirdly, all cells have AdoHcy hydrolase (Reaction 3，Fig. 1.2) and changes the tissue 
content of this enzyme or its inhibition may change the tissue content concentration of 
AdoHcy (Finkelstein, 1990). Upon AdoHcy degradation, adenosine and 
homocysteine are produced (De la Haba et al, 1959). 
Three enzymes utilize homocysteine as a substrate. Cystathionine P-synthase (CBS; 
Reaction 7, Fig. 1.2) diverts homocysteine to the irreversible transsulfuration pathway, 
and methionine synthase (MS; Reaction 4, Fig. 1.2) and betaine:homocysteine 
methyltransferase (BHMT; Reaction 6，Fig. 1.2) resynthesize methionine and thus 
conserve the homocysteine within the methionine cycle. All normal mammalian 
cells are able to synthesize 5-methyltetrahydrofolate (Reaction 5, Fig. 1.2), which act 
as a methyl donor in the MS reaction (Reaction 4, Fig. 1.2) (Finkelstein, 1990). MS 
is the intersection point for folate and cobalamin metabolism. In contrast, the 
distribution of BHMT is limited. It is only present in mammalian livers and primate 
kidneys (Finkelstein, 1990; McKeever et al, 1991). 
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Transsulfuration 
In the transsulfuration pathway, homocysteine is irreversibly converted to 
cystathionine by CBS (Reaction 7, Fig. 1.2), which requires pyridoxal-5-phosphate, 
an active form of vitamin B6. Cystathionine is further converted to cysteine by 
cystathionase (Reaction 8, Fig. 1.2). 
There are significant differences in the distribution of the transsulfuration enzymes: 
CBS and cystathionine y-lyase. In rats, neither enzyme is present in the heart, lung, 
testes, adrenal, nor spleen, but the brain and adipose tissue contain CBS, while 
cystathionine y-lyase is barely detectable (Finkelstein, 1990). Therefore, cysteine is 
an essential amino acid in these seven tissues. Only the liver, kidney, small intestine, 
and placenta have both transsulfuration enzymes. 
Cysteine formed from methionine and serine via transsulfuration and serves as a 
precursor for synthesis of essential molecules and protein. The essential molecules 
include GSH, coenzyme A, taurine and inorganic sulfate. 
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广Vlethylthioadenosine^ 
/ ATP^  
I \ Polyamines 
/ \ / >^glydn< AdoMet Y 
^ ^ ^ ^ V K V y METHIONINE 
C I C H 2 C H F ) Xthyl. m T；：^^^^ CYCLE 
^ o m o c y s t e i n ^ y 
® PLP 
TRANSSULFURATION 
PATHWAY 
Taurine ^ ^ ^ SO/ 
Fig. 1.2 Metabolic diagram of sulfur-containing amino acids. Numbered reactions are catalyzed 
by the following enzymes:(l) methionine adenosyltransferase (MAT); (2) 
5-adenosylmethionine-dependent methyltransferases (MT); (3) 5'-adenosylhomocysteine hydrolase 
(Adenosylhomocysteinase); (4) 5-methyltetrahydrofolate:homocysteine methyltransferase (MS); (5) 
5,10-methylenetetrahydrofolate reductase (MTHFR); (6) betainehomocysteine methyltransferase 
(BHMT); (7) cystathionine P-synthase (CBS); (8) cystathionine y-lyase (Cystathionase); (9) enzymes 
involved in polyamine synthesis; and (10) enzymes involved in methylthioadenosine salvage 
pathway. (Modified from Martha, 1999) 
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1.2.2. Metabolic Regulation of Homocysteine 
There are three mechanisms regulate the distribution of homocysteine: (1) differences 
in the tissue content of metabolic enzymes; (2) the inherent kinetic properties of the 
relevant enzymes and (3) the regulation by oxidation/ reduction state. 
Tissue Content of Enzymes 
Methionine metabolism is a cycle with three potential outlets formed by the synthesis 
of protein, AdoMet decarboxylase, and the CBS reaction (Finkelstein et al., 1967). 
Each of these outlets depends on the distribution of substrate between competing 
reactions at the three metabolic sites. In Section 1.2.1, it is noted that CBS is 
absent in the heart, lung, spleen, testes, and adrenal. Besides, since only liver has the 
high Km methionine adenosyltransferase III, it has the unique ability to synthesis 
AdoMet in response to a methionine load. Moreover, the distributions of BHMT are 
restricted. It is only present in mammalian livers and primate kidneys (Finkelstein, 
1990； McKeever et al, 1991). In addition, studies have shown that age, diet, and 
endocrine status can affect the tissue content of enzymes (Finkelstein et al., 1967; 
Finkelstein et al., 1971; Finkelstein et al., 1973; Finkelstein et al., 1978). As a result, 
the difference in enzyme distributions among tissues is the most obvious example for 
metabolic regulation. 
Kinetic Properties of the Enzymes � 
The kinetic property of an enzyme is regulated by several parameters, including the 
affinity for substrates, product inhibition, and the allosteric effector properties of the 
various metabolites. The "methionine conserving" enzymes have relatively low Km 
for their sulfur-containing substrates; are inhibited by their products; and are impaired 
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by AdoMet and possibly AdoHcy. Their hepatic content decreases with increased 
dietary methionine. They include methionine adenosyltransferase I and II, AdoHcy 
hydrolase, and MS. 
The enzymes of the "methionine catabolyzing" group have relatively high Km values 
for their sulfur-containing substrates, are not inhibited by their products, and are 
activated by AdoMet and AdoHcy. Their hepatic content increases in response to 
increased dietary methionine. These enzymes include methionine 
adenosyltransferase III, CBS, and cystathionine y-lyase. To make up the 
transsulfuration pathway, this group requires a methyltransferase that has a high Km 
for AdoMet, is relative insensitive to inhibition by AdoHcy, increases with increased 
dietary methionine and utilizes an available substrate to produce a nontoxic product 
that can be recycled to the substrate form. 
The effector properties of AdoMet and AdoHcy provide the basis for additional 
metabolic regulation. When the dietary methionine is abundant, intracellular 
concentrations of methionine and AdoMet will increase. AdoMet is a positive 
allosteric effector for CBS and a negative effector for both BHMT and 5， 
10-methylenetetrahydrofolate reductase (MTHFR). As a result, AdoMet plays an 
important role in diverting homocysteine into the transsulfuration pathway 
(Finkelstein et al., 1974). The net effect of AdoHcy on MS is unpredictable. 
AdoHcy is a potent inhibitor of most of the enzymes. However, it may enhance the 
synthesis of the substrate by releasing MTHFR from inhibition by AdoMet (Kutzbach 
et al., 1971). In vitro studies demonstrate that increasing concentrations of AdoHcy 
facilitates transsulfuration in liver (Finkelstein et al” 1984). 
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Regulation by Oxidation/ Reduction State 
The driving force of the regulation of distribution of homocysteine between 
transsulfuration and remethylation is the differential effect on MS and CBS of the 
oxidation/reduction state in the intracellular environment. MS is vulnerable to 
oxidation. In order to maintain its activity, periodic reductive methylation of MS is 
required (Chen et al, 1998). On the other hand, the activity of CBS increases in an 
oxidative environment (Taoka et al., 1998). Taken together, these observations 
suggest that the increased transsulfuration may be a metabolic response to oxidative 
stress. 
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1.3. Sulfur-Containing Amino Acids and Health 
Moderate elevation of total homocysteine concentration is an established independent 
risk factor for the development of vascular diseases (Clarke et al., 1991). 
Homocysteine is formed during methionine metabolism, and oral administration of 
methionine will increase plasma homocysteine. An exaggerated homocysteine rise 
following methionine loading may identify individuals at increased risk of vascular 
diseases (Dudman et al., 1993). Such elevation has also been associated with 
Alzheimer's disease (Clarke et al., 1998; Lehmann et al., 1999), renal diseases 
(Bostom et al., 1997; Dennis et al, 1996), as well as liver cirrhosis (Garcia-Trevijano 
et al., 2001). 
Homocysteine can'be remethylated to methionine that is considered one of the most 
toxic amino acids when it is fed to animals. Studies in rats have shown that 
prolonged high methionine intake causes growth failure and damage to liver, pancreas, 
and kidney (Benevenga, 1974; Harper et al, 1970). Yaghmai et al. (2002) suggested 
that the high methionine level might cause cerebral edema in which methionine 
competes with the transport of neutral amino acids into the cerebral spinal fluid (CSF), 
resulting in neutral amino acid deficiencies. Since the metabolism of homocysteine 
is 'greatly influenced by intracellular oxidation/ reduction state (see Section 1.2.2), 
this factor could also play an important role in health and disease caused by this 
amino acid. 
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1.3.1. Sulfur-Containing Amino Acids and Renal Diseases 
Sulfur-containing amino acids show many abnormalities in chronic renal failure. 
Among these, high levels of plasma total homocysteine have attracted special 
attention because it is a risk factor for atherosclerosis. Cysteine is also associated 
with renal failure. Study showed that hyperhomocysteinemia in uremic patients is 
associated with high levels of plasma total cysteine, which are correlated with plasma 
total homocysteine levels (Suliman et al., 2000) 
Plasma total homocysteine is elevated in renal disease (Bostom et al, 1995; Hultberg 
et al., 1993; Wilcken et al., 1980). Studies using plasma clearance methods for 
estimation of renal function showed a significant and inverse correlation between the 
plasma homocysteine concentrations and the glomerular filtration rates through 
almost the entire renal functional range in health and disease (Amadottir et al., 1996; 
Wollesen et al., 1999). 
The potential mechanisms associated with uremic hyperhomocysteinemia include 
increased cellular production or delayed plasma clearance (Guttormsen et al., 1997), 
and delayed cellular uptake (Canestrari et al., 1995; Ceballos-Picot et al, 1996; 
Hultberg et al., 1994; Hultberg et al., 1995). 
Increased Cellular Production or Delayed Plasma Clearance 
Hyperhomocysteinemia can be induced either by increased cellular release or by 
decreased plasma clearance. A study based on the homocysteine loading test 
showed that the homocysteine half-life and urea under the time-concentration curve of 
uremic patients was about four times higher than that of the healthy control subjects. 
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Besides, the plasma clearance of uremic patients was reduced to about 30 % when 
compared with control subjects (Guttormsen et al., 1997). These results demonstrate 
that delayed plasma clearance is a dominating influence on homocysteine metabolism 
in renal disease patients (Guttormsen et al., 1997). 
Delayed Cellular Reuptake 
Circulating homocysteine can be taken up by cells for removal because the relevant 
enzymes are located intracellularly (McKeever et al., 1991). Conceivably, cellular 
uptake could be impaired. Although the total and free homocysteine are increased in 
renal failure, that of reduced homocysteine is not (Andersson et al., 1999; Hultberg et 
al., 1995). Studies have shown that the less reduced homocysteine was due to the 
increased oxidative stress in uremic plasma (Canestrari et al., 1995; Ceballos-Picot et 
al., 1996). As homocysteine is mainly present in its reduced form (Hultberg et al., 
1994), the high oxidative capacity of uremic plasma may slow the cellular uptake of 
circulating homocysteine. 
Homocysteine can be remethylated to methionine. Studies in rats have shown that 
prolonged high methionine intake causes growth failure and damage to liver, pancreas, 
and-kidney (Benevenga, 1974; Harper et al., 1970). Thus, the remethylation to 
methionine may be a contributing factor to renal failure. 
Besides, taurine is also related to renal disease. Taurine is one of the most abundant 
free intracellular amino acids in mammalian tissue. In uremic patients, low taurine 
levels in the muscle, plasma (Divino et al., 1997)，and platelets (Jung et al., 1997) 
have been reported, while the taurine concentrations in erythrocytes is high (Divino et 
al., 1997). Although the consequences of taurine depletion in the end-stage renal 
, 12 
Chapter 36 Introduction 
disease patients are unknown, one may deduce that taurine depletion might contribute 
to muscle fatigue and cardiovascular disease in uremia. 
1.3.2. Sulfur-Containing Amino Acids and the Nervous System 
Studies have shown that homocysteine, cysteine, and other sulfur-containing 
metabolites including homocysteine thiolactone, homocysteic acid, and homocysteine 
sulfmic acid can cause convulsions and acts as excitatory agonists on the 
A^-methyl-D-aspartate (NMDA) subtype of the glutamate receptor (Grandes et al, 
1991; Wuerthele et al., 1982) in the nervous system. 
Some studies indicated that there was a strong, graded association between plasma 
total homocysteine levels and the risk of dementia and Alzheimer's disease. An 
increment in the plasma homocysteine level of 5 ^mol/L increased the risk of 
Alzheimer's disease by 40 %. The phenomenon appeared to be independent of age, 
sex, apolipoprotein E genotype, plasma vitamin levels and other putative risk factors 
for dementia and Alzheimer's disease (Seshadri et al” 2002). 
The potential mechanisms by which homocysteine can cause neuronal injury are 
shown in Fig. 1.3. Hyperhomocysteinemia has been related to cerebral 
microangiopathy (Fassbender et al, 1999), endothelial dysfunction (Welch et al, 
1998), impaired nitric oxide activity (Chao et al” 2000), and increased oxidative stress 
(Starkebaum et al., 1986). Homocysteine also promotes copper-mediated and 
(beta)-amyloid-peptide-mediated toxic effects in neuronal cell cultures (White et al., 
2001) and induces apoptosis in hippocampal neurons in rats (Kruman et al., 2000). 
Homocysteic acid, a metabolite of homocysteine, can also cause neuronal 
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excitotoxicity by stimulating NMDA receptors (Lipton et al., 1997). In addition, the 
effects of homocysteine on atherothrombosis in the cerebral vasculature promote 
central nervous system ischemia, neuronal hypoxia and injury (Loscalzo, 2002). 
二 1 鄰 絡 Homocysteine � . 
"” ：， / / L Cerebral artery ) 
Neuron | C �, ^ / 乂 ^ ^ ^ 
sC、、；， 11 CNS Ischemia,^ Endothelial dysfunction, 
二 i neuronal hypoxia atherothrombosis 
… �A , V、：、 、、 
、、：.办/ 〜、*於 . 
Fig. 1.3 Potential mechanisms by which homocysteine can cause neuronal injury 
(Modified from Loscalzo, 2002) 
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Besides high levels of homocysteine, a relatively large dose of methionine might 
bring about severe and potentially lethal cerebral effects. Yaghmai et al. (2002) 
described the case of a 10-year-old CBS-deficient girl whose plasma methionine rose 
to concentrations close to 3000 i^mol/L while she was being treated with betaine and 
was noncompliant with dietary methionine restriction and she developed massive 
cerebral edema. The mechanisms in which the elevation of methionine or its 
metabolites might cause cerebral edema are not known. Yaghmai et al (2002) 
suggested that high methionine might cause cerebral edema by competing with the 
transport of neutral amino acids into the CSF，resulting in amino acid deficiencies. 
Study showed that glutamine, a neutral amino acid, was associated with edema. 
Picker et al. (2003) described a case of argininase deficiency in a 2-day-old female 
infant with encephalopathy and cerebral edema. The levels of glutamine and 
arginine but not ammonia were significantly increased, lending support to the 
"glutamine hypothesis" (Albrecht et al., 2001), which hypothesizes that glutamine 
enters the astrocyte and exerts an osmotic effect, as the mechanism of cerebral edema 
in urea cycle defects. Study also demonstrated that by using methionine sulfoximine 
to-block glutamine production by the intra-astrocyte localized glutamine synthetase 
enzyme could suppress astrocyte swelling and cerebral edema, this further supported 
for the toxic edematous effect of glutamine (Willard-Mack et al., 1996). 
Taurine is one of the abundant free sulfur-containing amino acids in the central 
nervous system and is thought to play a role as an osmoregulator (Tuz et al., 2001) 
and a neuromodulator (Oja and Saransaari, 1996). Taurine is also known to exert a 
neuroprotective effect against excitotoxic agents (French et al., 1986) and oxidative 
stress (Boldyrev et al., 1999). The taurine level in brain interstitial fluid is elevated 
in ischemia (Uchiyama-Tsuyuki et al., 1994; Matsumoto et al., 1996; Nakane et al., 
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1998), indicating that the brain controls its taurine level in response to cell damage for 
protecting neurons. 
1.3.3. Sulfur-Containing Amino Acids and Heart Diseases 
As early as 1969, clinical studies conducted in homocystinuric children revealed the 
importance of severe hyperhomocysteinemia in premature development of 
atherosclerosis and thromboembolism (McCully, 1969). Clarke et al. (1991) 
measured homocysteine concentrations after methionine loading in a cohort of men 
with premature vascular disease and normal controls and demonstrated that 42 % of 
patients with cerebrovascular disease, 28 % of patients with peripheral vascular 
disease, and 30 % of patients with coronary artery disease had hyperhomocysteinemia. 
Furthermore, using'data from a large European case-control study, El-Khairy et al. 
(2001) demonstrated that total cysteine was associated with vascular diseases in the 
coronary, cerebral, and peripheral arteries. 
Results from animal and cell culture studies indicated that increased homocysteine 
concentrations might accelerate coronary heart disease by various mechanisms, 
including, stimulation of smooth muscle cell proliferation (Tsai et al., 1994)，direct 
damage to the vascular endothelium (Harker et al., 1976) and enhanced low-density 
lipoprotein (LDL) peroxidation (Olszewski et al., 1993). In addition, homocysteine 
has been shown to increase DNA synthesis in vascular smooth muscle cells consistent 
with early arteriosclerotic lesions and to induce these cells to proliferate while 
impeding the regeneration of endothelial cells and to cause LDL oxidation (Heinecke 
et al, 1984; Parthasarathy, 1987; Tsai et al, 1994). Homocysteine may also interfere 
with homeostasis by several mechanisms hence contributing to a biochemical 
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environment inductive to thrombus formation (Fryer et al, 1993; Hajjar, 1993; Lentz 
et al., 1993; Rodgers et al, 1986). The effects of homocysteine on vascular 
hemostatic properties have included decreased thrombomodulin cell surface 
expression and inhibition of protein C activation (Rodgers et al” 1990), thus probably 
contributing to development of thrombosis (Lentz et al., 1991). The potential 
mechanisms in which homocysteine cause heart diseases are summarized in Fig. 1.4. 
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Fig. 1.4 Possible adverse vascular effects of homocyst(e)ine. LDL; low-density 
lipoprotein. (Modified from Welch et al., 1998) 
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Homocysteine can be converted to cysteine, which shares similar structural and 
chemical properties with homocysteine. Autoxidation of cysteine in vitro promotes 
several processes, such as generation of free radicals and hydrogen peroxide, 
considered to be involved in atherogenesis and thrombogenesis (Heinecke et al., 1987; 
Hogg, 1999; Starkebaum et al , 1986; Tsai et al., 1994; Welch et al., 1997). Cysteine 
supports superoxide-mediated modification of LDL, which may facilitate foam cell 
formation (Heinecke et al., 1987; Parthasarathy, 1987). Besides, cysteine has a 
cytotoxic effect in vitro against several cell types (Nishiuch et al., 1976). 
Furthermore, cysteine forms an adduct with nitric oxide (Sheu et al., 2000) and may 
thereby impair endothelial function. On the other hand, homocysteine can be 
remethylated to methionine. Study has shown that dietary supplementation with 
methionine and homocysteine promotes early atherosclerosis (Zhou et al., 2001). 
Taurine is widely distributed in animal tissues. Epidemiological study suggested it 
has beneficial effect on preventing cardiovascular disease (Yamori et al., 1987). 
Several studies have reported that taurine stimulates bile acid synthesis and, thereby, 
decreases in plasma cholesterol levels in which may prevent the development of 
atherosclerosis (Murakami et al. 1996; Sugiyama et al., 1984; Yamanaka et al., 1986). 
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1.3.4. Sulfur-Containing Amino Acids and Liver Diseases 
The liver plays a fundamental role in the synthesis and metabolism of homocysteine 
and other sulfur-containing amino acid and displays a specific pattern of expression of 
genes involved in methionine and homocysteine metabolism. There are two genes 
coding for methionine adenosyltransferase (MAT) which converts methionine into 
AdoMet; MATIA is expressed in the liver only while MAT2A is expressed in all 
tissues (Mato et al., 1997). BHMT and CBS expression are confined mainly to the 
liver, whereas MS is widely expressed in all tissues (Finkelstein, 1990). Therefore, 
it is likely that in the situation of liver damage, alterations in homocysteine 
metabolism may occur. Indeed, hyperhomocysteinemia has been observed in 
chronic alcoholics and in patients with alcoholic cirrhosis, as well as in experimental 
models of liver damage (Cravo et al” 1996; Varela-Moreiras et al., 1995). 
Garcia-Trevijano et al. (2001) showed that alterations in homocysteine metabolism in 
human liver cirrhosis could be ascribed, in part, to a marked reduction in the 
expression of the major genes involved in its metabolism, namely MS, BHMT and 
CBS. They also observed a decrease in MATIA expression in cirrhotic liver, which 
explained the reported hypermethioninemia and impairment of AdoMet synthesis. 
Taken together, their observations suggested impaired liver function could be a 
determinant in the development of hyperhomocysteinemia and the elevated 
homocysteine levels played a role in the.liver fibrosis development. 
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1.4. Vitamin C (Ascorbic Acid) 
Antioxidant vitamins, including A, C, E, play a crucial role in maintaining health. 
Research has shown that antioxidant vitamins, particularly vitamin C, play a 
protective role in clinical circumstances such as cardiovascular diseases, cancer, and 
renal disorders (Carr and Frei, 1999). Vitamin C is an essential micronutrient 
required for the normal metabolic function of the body and exists in two physiological 
forms as I-ascorbic acid, the reversibly reduced form, and dehydroascorbic acid 
(DHA), the reversibly oxidized form (Carr and Frei, 1999). 
The reduced form of vitamin C is a cofactor for many important enzymes acting to 
2+ + • 
maintain transition metal ions in their reduced form (for example, Fe and Cu ) and is 
involved in several metabolic roles including the biosynthesis of extracellular matrix 
proteins and neurotransmitters, and the regulation of iron uptake (Packer and Fuchs, 
1997; Toth and Bridges, 1995). Ascorbic acid is also a good reducing agent and it is 
the most important water-soluble antioxidant in human plasma. This is because 
ascorbic acid can easily give up two hydrogens with their electrons thereby becoming 
dehydroascorbic acid (Frei et al., 1989). Free radicals combine with vitamin C 
instead of causing oxidative damage to the cells. The reversibility of the reaction is 
important to vitamin C's role as an antioxidant (Fig. 1.5). Being an antioxidant, 
ascorbic acid readily scavenges nitrogen species, such as superoxide and 
hydroperoxyl radicals, and other reactive oxygen species, thus effectively protecting 
other substances from oxidative damage (Packer and Fuchs, 1997; Retsky et al., 
1993). 
Vitamin C can also act as a coantioxidant by regenerating a-tocopherol (vitamin E) 
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from the a-tocopheroxyl radical, produced via scavenging of lipid-soluble radicals 
(Bowry et al., 1995; Packer, 1997). Vitamin C has also been shown to regenerate 
urate, glutathione, and p-carotene in vitro from their respective one-electron oxidation 
products, i.e., urate radicals, glutathiyl radicals, and p-carotene radical cations (Edge 
et al., 1997; Halliwell, 1996). Deficiency of ascorbic acid in humans leads to a 
wide variety of clinical abnormalities, such as, scurvy, poor wound healing and bone 
and connective tissue disorders (Packer and Fuchs, 1997). 
j^ l O 
H 0 \ / C \ / 2H Ox C \ 
\ c o • ^ C ^ o 
I I / I — / 
/ C - C H \ 2 h + 0 - C C|H 
HO HO ——CH 
„ HO——CH 
CH2OH 
CH2OH 
Ascorbic acid Dehydroascorbic acid 
Fig. 1.5 Interconvertion between ascorbic acid and dehydroascorbic acid 
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1.4.1. Biosynthesis 
The biosynthesis of ascorbic acid occurs in the liver of mammals. Other tissues are 
supplied with ascorbic acid via uptake from the plasma. Most animals, including the 
rat，are able to synthesis ascorbic acid by converting D-glucose into L-ascorbic acid 
(Bock et al., 1974; Bums et al., 1956; Horowitz et al., 1953; Isherwood et al., 1954). 
D-glucose is converted into I-ascorbic acid via Z)-glucuronic acid, L-gulonic acid, 
L-gulonolactone, and 2-keto-I-gulonolactone as intermediates (Horowitz et al., 1953). 
In vitro and in vivo studies have shown that ascorbic acid biosynthesis is controlled by 
a direct feedback mechanism, and that the concentration of ascorbic acid in cell 
culture medium or in the blood regulates the amount of ascorbic acid synthesized in 
the liver or in hepatocytes of rat and mice (Bissell et al., 1979; Bock et al, 1974; Tsao 
et al., 1990). The biosynthetic pathway of ascorbic acid is shown in Fig. 1.6. 
Human, primates, guinea pigs have lost the ability to synthesize vitamin C as a result 
of lacking of L-gulono-y-lactone oxidase, an enzyme required for the biosynthesis of 
vitamin C, and thus, depend on a dietary source in order to maintain good health 
(Packer and Fuchs, 1997). 
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Fig. 1.6 Biosynthesis of ascorbic acid 
1.4.2. Vitamin C Transport System 
Cellular ascorbic acid accumulation occurs through two transport mechanisms: either 
by direct uptake of ascorbic acid, or by uptake of dehydroascorbic acid followed by 
intracellular reduction of ascorbic acid. There are two types of membrane transport 
activity have been described for the entry of vitamin C into mammalian cells: 
transport by a high affinity/low-capacity active carrier, and low-afFinity/high-capacity 
facilitative carrier. The high-affinity carrier is a Na+-dependent transport system that 
accepts only the reduced ascorbate as the substrate, namely, sodium-dependent 
vitamin C transport protein (SVCT) (Diliberto et al., 1983; Helbig et al., 1989; Prasad 
et al., 1998; Siliprandi et al., 1979; Wilson and Dixon, 1989). Two isoforms of this 
transport protein, SVCTl and SVCT2, have been recently isolated. The low-affinity 
carrier is a Na+-independent system mediated by the facilitative glucose transporters 
(GLUT). One of the substrates for this system is dehydroascorbic acid (Rumsey et 
al., 1997; Vera et al., 1993). 
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1.4.2.1. Uptake of Ascorbic Acid 
Uptake of ascorbic acid via sodium-vitamin C co-transporters (SVCT), SVCTl and 
SVCT2, is absolutely dependent on the presence of Na+. Using radioactively labeled 
ascorbate, an independent concentrative uptake system for the reduced ascorbate has 
been established in guinea pig intestinal mucosal cells, human small intestinal 
brush-border membrane vesicles, rat osteoblasts, human neutrophils and fibroblasts, 
3T6 mouse fibroblasts, bovine granulose-leutin cells, astrocytes, and human 
granulose-leutin cells (Goldenberg and Schweinzer, 1994; Helbig et al., 1989; Malo 
and Wilson, 2000; Padlh and Aleo, 1987; Siliprandi et al., 1979; Welch et al., 1995; 
Wilson and Dixon, 1989; Wilson et al., 1991; Zreik et al., 1999). 
SVCTl and SVCT2 are each saturable, exhibiting high apparent affinity for 
I-ascorbic acid, and Na+-dependent with stoichiometry of 2 Na+: 1 丄-ascorbic acid. 
SVCTl is a 604 amino acid protein and has a limited distribution, mainly confined to 
the bulk transporting epithelia, such as kidney, intestine and liver (Daruwala et al., 
1999; Faaland et al, 1998; Tsukaguchi et al., 1999). Besides, northern analysis 
using a commercially available multiple tissue RNA blot indicated that the 
SVCTl-specific transcript was present in the liver and kidney, while the heart, brain, 
placenta, lung, skeletal muscle and pancreas were devoid of any detectable 
SVCTl-specific transcripts (Wang et al, 1999). SVCT2 is a 592 amino acid protein 
that shares 65 % homology to SVCTl and displays a much broader distribution in the 
brain, retina, spleen, leukocytes, as well as in several endocrine tissues and 
neuroendocrine tissues (Wang et al., 1999). 
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1.4.2.2. Uptake of Dehydroascorbic Acid 
The structure of dehydroascorbic acid (DHA) is similar to glucose, and its entry into 
cells can be competitively inhibited by sugars (Vera et al., 1995). These findings 
suggest that entry of DHA is mediated by glucose transporters. Early 
characterization of DHA transport was performed with a Xenopus laevis oocyte 
expression system that expressed the facilitated-diffusion glucose transporter isoforms, 
GLUT 1-5 (Bimbaum et al., 1986; Fukumoyo et al, 1988; Fukumoto et al., 1989; 
Kayano et al., 1988; Kayano et al., 1990), and the Na+-dependent glucose transporter 
(SGLTl) (Hediger et al., 1987). Further studies showed that GLUTl and GLUT3 
mediated DHA transport with a similar efficiency to that of glucose (Rumsey et al., 
1997). GLUT4 also transported DHA with a higher affinity than 2-deoxyglucose, 
but with a 13-fold： lower V^ax (Rumsey et al., 2000). GLUT2, GLUT5 and SGLTl 
did not transport DHA, and none of the glucose transporter isoforms transported 
ascorbic acid (Rumsey et al., 1997). There are differences in the tissue distributions 
of GLUTl and GLUTl GLUTl has wide tissue distribution (Gould et al., 1993; 
Mueckler et al., 1994), while GLUT3 is primarily expressed in the brain, placenta, 
testis, and platelets (Craik et al., 1995; Haber et al., 1993; Macher et al., 1994; 
Shepherd et al, 1992; Zhou et al., 1993). 
Under physiological conditions, ascorbic acid, the reduced form, predominates, and 
therefore, it is highly unlikely that GLUT-mediated vitamin C transport will suffice 
the cellular needs for the vitamin (Dhariwal et al., 1991; Rose, 1988). Moreover, 
circulating levels of glucose are 1000-fold higher than the levels of DHA, and thus 
marked competition by glucose of DHA influx will occur. However, DHA formed 
by oxidation of ascorbic acid in the tissue microenvironment might lead to locally 
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high concentration of DHA that crosses the blood-brain barrier via GLUT transporters 
(Agus et al., 1997). It was demonstrated that astrocytes take up DHA through the 
GLUTl (Siushansian et al., 1997). Upon transported into astrocytes, DHA is 
reduced to ascorbic acid but the mechanism involved is unclear. Ascorbic acid may 
also be released to the extracellular fluid by astrocytes stimulated under physiological 
or pathological conditions. This mechanism represents an important process by 
which vitamin C enters the brain (Korkok et al., 2000; Qutob et al, 1998; Wilson, 
1997). Neurons also express two different glucose transporters (GLUTl and 
GLUT3) in fetal and adult brain (Aller et al., 1997; Mueckler, 1994; Nualart et al., 
1999), which take up DHA (Rumsey et al., 1997). Since the transport of DHA 
through the glucose transporters can occur in either direction (Rose, 1988; Vera et al., 
1995; Rumsey et al., 1997), the cell must trap the vitamin C molecule in its reduced 
form, ascorbate. ‘ Once in neuron, DHA is reduced by a yet-to-be-determined 
mechanism and trapped as ascorbic acid. A potential mechanism involving 
glutathione and other different reducing enzymes has been proposed for the 
interconvertion of oxidized and reduced form of vitamin C (Del Bello et al., 1994; 
Winker, 1992). 
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1.5. Vitamin C and Health 
Oxidative damages induced by reactive oxygen species are caused by increased 
production of superoxide anion and its metabolites and/or by reduced bioavailability 
of antioxidants. This imbalance between pro-oxidants and antioxidants gives rise to 
cellular oxidative stress, which plays an important role in the pathogenesis. Vitamin 
C is a major naturally occurring antioxidant, essential for the scavenging of toxic free 
radicals in the plasma and tissues (Frei et al., 1988), thus it is an important antioxidant 
in preventing oxidative stress. 
1.5.1. Vitamin C and Heart Diseases 
Epidemiological - studies have demonstrated an inverse relationship between 
cardiovascular disease and dietary intake of essential vitamins, such as vitamins C and 
E. In Britain, for example, rates of stroke and coronary heart disease are highest in 
regions where consumption of fruits and vegetables is lowest (Acheson et al., 1983; 
Armstrong et al., 1975). 
Vitamin C may retard atherosclerosis by protecting against the oxidation of LDL by 
free radicals (Ross, 1993; Witztum, 1994). Oxidized LDL is taken up more readily 
than native LDL by macrophages to create foam cells. Oxidized LDL also inhibits 
the motility of tissue macrophages, is chemotactic for circulating monocytes, and 
damages endothelial cells (Steinberg, 1993). Vitamin C has also been shown to raise 
high-density lipoprotein, lowers total cholesterol and improves blood pressure (Harats 
et al., 1988; Moran et al., 1993). All these are important factors related to cardiac 
diseases. Various studies suggested a synergism between vitamin C and vitamin E in 
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defending against LDL oxidation: vitamin C regenerates vitamin E from its oxidized 
form, making it available to act as an antioxidant once again. Moreover, vitamin C 
has also been shown to improve endothelial-dependent vasodilation (Timimi et al., 
1998) and reduce superoxide production (Nunes et al., 1997). In Section 1.3.3, it is 
noted that high levels of sulfur-containing amino acids, particularly homocysteine, are 
risk factors of heart diseases, whereas the above clearly suggests vitamin C has 
beneficial effects on heart diseases. Therefore, it is worth to determine the 
relationship between sulfur-containing amino acids and vitamin C. 
1.5.2. Vitamin C and Renal Diseases 
Several studies indicated that vitamin C levels were decreased in patients with chronic 
renal failure, dialysis patients, and patients after renal transplantation (Bohm et al., 
1997; Wang et al, 1999). Besides, animal studies have shown that oxidative stress 
has been associated with age-related glomerular sclerosis (Reckelhoff et al., 1998; 
Ruiz-Torres et al , 1997), ischemic kidney injury (Uysal et al., 1998), diabetic 
nephropathy (Kakkar et al., 1997)，and hypertensive nephropathy (White et al., 1998). 
Supplementation with antioxidant vitamins has been recommended for the prevention 
and treatment of chronic renal failure (Hegbrant et al., 1999; Wardle, 1999). 
Oxidative stress has been associated with renal insufficiency in animal studies 
(Ruiz-Torres et al., 1997; White et al., 1998). Vitamin C plays an important role in 
preventing the progression of renal insufficiency by alleviating oxidative stress and 
renal cell injury (Frei et al., 1989; Nowak et al., 2000). Chronic renal failure is 
associated with impaired endothelium-dependent vasodilation and accelerated 
atherogenesis (Agodoa, 2000; Brown et al., 1994)，Cross et al. (2003) demonstrated 
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that acute administration of vitamin C reduced the levels of oxidant stress in renal 
failure and improved nitric oxide (NO)-mediated resistance vessel dilatation. 
Vitamin C might increase NO bioactivity by several mechanisms, such as increased 
NO production (Baker et al., 2001; Heller et al., 1999; Huang et al., 2000), release of 
NO from endogenous NO thiols, or protection of NO from premature deactivation by 
combination with superoxide. In Section 1.3.1, it is noted that high levels of 
sulfur-containing amino acids are associated with renal diseases, while the above 
suggest that the beneficial effects of vitamin C in renal diseases; thus, it is important 
to investigate the relationship between sulfur-containing amino acids and vitamin C. 
1.5.3. Vitamin C and Brain Diseases 
The prevalence of Alzheimer's disease is increasing in the Western world. 
Pathological oxidation has been proposed to be an important factor in its pathogenesis 
(Mark et al., 1996; Markesbery, 1997; Multhaup et al, 1997). Studies have shown 
that brain tissue from Alzheimer's disease patients possessed higher levels of oxidized 
proteins (Smith et al., 1991), advanced glycation end products (Montine et al., 1997) 
and products of lipid peroxidation (Lovell et al., 1995; Sayre et al., 1997) than tissue 
from non-demented elderly controls. Oxidation can impair patients' normal brain 
function and that oxidized lipoprotein can be toxic for neuronal cells (Bassett et al., 
1999; Draczynska-Lusiak et al., 1998). In addition to the increase oxidizability, a 
decrease in ascorbate and a-tocopherol in both CSF and plasma was observed in 
Alzheimer's disease patients (Schippling et al., 1999; Schippling et al., 2000). 
One study demonstrated that the combined supplementation of Alzheimer's disease 
patients with vitamins E and C was able to increase their concentrations in CSF and 
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plasma, returned vitamin C to its normal levels, and thus decreased in vitro 
oxidizability of CSF and plasma lipoproteins (Kontush et al., 2001). Ascorbate is a 
major hydrophilic antioxidant in human CSF and protect against lipoprotein oxidation 
in brain (Schippling et al., 2000). This protection is due to the recycling of 
lipoprotein-located a-tocopheroxyl radicals, as well as direct scavenging of other free 
radicals (Stocker, 1994). In Section 1.3.2, it is noted that high levels of 
sulfur-containing amino acids are associated with Alzheimer's disease, while the 
above demonstrate the beneficial effects of vitamin C in preventing Alzheimer's 
disease. Since the relationship between sulfur-containing amino and vitamin C 
remains obscured, it is worthy of examination. 
1.5.4. Vitamin C and Liver Diseases 
Human liver cancer often develops after the onset of chronic hepatitis and the 
subsequent cirrhosis. An increase in serum thiobarbituric acid reactive substances 
(Higueras et al., 1994), a marker of oxidative damage of lipids, and reduced level of 
plasma and erythrocyte glutathionine (Shigesawa et al., 1992; Swietek et al., 1997) 
was observed in patients with acute and chronic hepatitis. Patients with severe 
hepatitis have reduced levels of vitamin E (Von Herbay et al., 1996). In addition, 
study showed that a significant decrease in plasma ascorbic acid level was observed in 
patients with hepatitis, cirrhosis, and hepatoma as compared with normal subjects 
(Yamamoto et al., 1998). This indicated that these patients were subject to oxidative 
stress as ascorbic acid was the most oxidatively vulnerable antioxidant in human 
plasma (Frei et al., 1988; Yamamoto et al” 1991). A significant decrease in plasma 
ascorbic acid levels was also observed (Yamamoto et al, 1997) in Long-Evans 
cinnamon rat, an animal model of hepatitis and liver cancer. The lowered vitamin C 
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levels in these patients may be due to free radical-mediated liver injury. 
Since high levels of sulfur-containing amino acid are associated with certain liver 
diseases (see Section 1.3.4) and that vitamin C is effective in preventing liver diseases 
by scavenging the free radicals, these two parameters may be related. Indeed, it was 
demonstrated that a high-dose vitamin C with pre-treatment of vitamin E was very 
effective in preventing catalase exhaustion and protecting against 
ischemia-reperfusion injury in the liver (Keams et al., 1999; Ozaki et al., 1995). 
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1.6. The Aims of Project 
Antioxidants vitamins, such as A, C, E，play a crucial role in maintaining health. 
Studies have shown that antioxidant vitamins, particularly vitamin C, can prevent 
heart diseases, vascular dementia, as well as progressive renal insufficiency (Carr and 
Frei, 1999). Recently, accumulated evidence shows that elevated plasma 
homocysteine (Hey) concentration, a reflection of impaired cellular metabolism, is 
associated with premature cerebrovascular, peripheral and coronary artery diseases 
(Cattaneo, 1999; Refsum et al., 1998) as well as Alzheimer's disease (Clarke et al., 
1998; Lehmann et al” 1999) and certain renal disorders (Bostom et al., 1997; Dennis 
et al., 1996). However, the relationship between Hey and other sulfur-containing 
amino acids and antioxidant vitamins in tissues remains obscured. 
In this study, the effects of Hey and other sulfur-containing amino acids, including 
cysteine (Cys), methionine (Met) and taurine (Tau), on ascorbic acid status were 
investigated in male BALB/c mice. I-Cys is a natural occurring amino acid; it has a 
sparing effect on 丄-Met, while D-Cys does not. D-Cys was included to determine if 
stereospecificity exists. Since D-amino acids are consumed by animals and humans 
as part of their normal diets, a need exists to develop a better understanding of their 
roles. In order to determine whether the changes on ascorbic acid status were 
limited to sulfur-containing amino acids, leucine (Leu), an essential amino acid, was 
also investigated. Mice were assigned to receive Met (100 mg/kg/d), Hey (100 
mg/kg/d), L- and D-Cys (100 mg/kg/d), Tau (100 mg/kg/d), Leu (100 mg/kg/d) and 
saline (control group) intraperitoneally for 7 days, and changes in ascorbic acid 
concentrations in the plasma, heart, brain, kidney and liver were analyzed 
(Garcia-Tevijano et al., 2001; Kokkinakis et al., 1997). To investigate the effects of 
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the treatments on vitamin C levels in a relatively shorter and longer period of time, 1 
day and 14 days intraperitoneal (i.p.) injections were also performed. 
Cellular ascorbic acid accumulation occurs through two facilitated transport 
mechanisms: either by direct uptake of ascorbic acid or by uptake of dehydroascorbic 
acid, followed by intracellular reduction to ascorbic acid. A sodium-dependent 
vitamin C transport protein (SVCT) mediates direct ascorbic acid transport. Two 
isoforms of this transport protein, named SVCTl and 2, have recently been isolated 
from the rat. SVCTl is predominant in the liver and kidney and SVCT2 is found in 
the brain and heart. In the brain, dehydroascorbic acid is taken up using the glucose 
transporters (GLUTl and 3). Upon transport into the brain, dehydroascorbic acid is 
reduced to ascorbic acid. To date, there have been no studies characterizing the 
effects of sulfur-containing amino acids on the changes on SVCT and GLUT gene 
expressions. In the present study, we focused on determining the effects of 
sulfur-containing amino acids and leucine on the gene expressions of SVCT and 
GLUT in various tissues. 
Furthermore, in order to establish if there were any correlations between the levels of 
sulfur-containing amino acids, leucine and the changes of ascorbic acid status, the 
sulfur-containing amino acids and leucine concentrations in the plasma were 
determined by amino acid analyzer. 
The ultimate goal in this project was to find out the relationship, if any, between 
sulfur-containing amino acids and ascorbic acid. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1. Materials 
The sources of the chemicals used in this study are summarized in Table 2.1. 
(a) Ascorbic Acid Analysis 
Metaphosphoric acid (NaPOs) Sigma Chemical Co., U.S.A. 
Isoascorbic acid (lA) Sigma Chemical Co., U.S.A. 
Cysteine (Cys) Sigma Chemical Co., U.S.A. 
： 
Perchloric acid (PA) BDH Chemicals Ltd., England 
Mobile phase: 
Sodium acetate Merck, Germany 
Ethylenediaminetetraacetic acid disodium Koch-Light Chemical Ltd., England 
salt hydrate (Na2EDTA) 
Dodecyltriethylammonium phosphate Regis Tech Inc., U.S.A. 
Methanol (HPLC grade) BDH Chemicals Ltd., England 
Glacial acetic acid Sigma Chemical Co., U.S.A. 
(b) Amino Acid Analysis 
Sulfosalicylic acid (SSA) Sigma Chemical Co., U.S.A. 
.Mobile phase: 
Li-A Beckman -Coulter (Fullerton, CA) 
Li-B Beckman -Coulter (Fullerton, CA) 
Li-C Beckman -Coulter (Fullerton, CA) 
Li-R Beckman -Coulter (Fullerton, CA) 
Ninhydrin reagent Beckman -Coulter (Fullerton, CA)  
Li-S Beckman -Coulter (Fullerton, CA)  
Calibration standards: 
STD Beckman -Coulter (Fullerton, CA) 
AN+ Beckman -Coulter (Fullerton, CA) 
B+ Beckman -Coulter (Fullerton, CA) 
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(c) RNA extraction and reverse transcription-polymerase chain reaction 
(RT-PCR)  
TRIzol Invitrogen, Hong Kong 
Chloroform AnalaR, England 
Isopropanol Promega, U.S.A. 
Ethanol AnalaR, England 
Nuclease-free water Promega, U.S.A. 
Random primers Roche, Germany 
Deoxynucleotide mix (dNTP) Roche, Germany 
AMV reverse transcriptase Roche, Germany 
RNAse inhibitor Roche, Germany 
Magnesium chloride (MgCb) Roche, Germany 
Taq polymerase Roche, Germany 
Sense and antisense primers TechDragon, Hong Kong 
Agarose Sigma Chemical Co., U.S.A. 
Loading dye: 
Ethidium bromide Bio-Rad, U.S.A. 
Bromophenol blue MERCK, Germany 
„ Ethylenediaminetetraacetic acid (EDTA) Sigma Chemical Co., U.S.A. 
Glycerol Sigma Chemical Co., U.S.A 
100 bp DNA ladder marker Bio-Rad, U.S.A. 
Tris-borate EDTA (TBE) buffer: 
Boric acid Sigma Chemical Co., U.S.A 
EDTA Sigma Chemical Co., U.S.A 
Tris Sigma Chemical Co., U.S.A 
(d) Amino acids and other chemicals 
Methionine Sigma Chemical Co., U.S.A 
Homocysteine Sigma Chemical Co., U.S.A 
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I-Cysteine Sigma Chemical Co., U.S.A 
/^-Cysteine Sigma Chemical Co., U.S.A 
Taurine Sigma Chemical Co., U.S.A 
Leucine Sigma Chemical Co., U.S.A 
Ascorbic Acid Sigma Chemical Co., U.S.A. 
Table 2.1 The chemicals used in this study and their sources 
2.2. Preparation of Materials 
2.2.1. Mobile Phase for Ascorbic Acid Analysis 
The mobile phase was prepared by adding 40 mM sodium acetate, 0.54 mM 
ethylenediaminetetraacetic acid disodium salt hydrate (NasEDTA), 1.5 mM 
dodecyltriethylammonium phosphate and 7.5 % methanol, taken to pH 4.75 with 
glacial acetic acid. It was filtered through a 0.2 i^m filter (Micro Filtration Systems, 
Dublin, USA) prior to use. 
2.2.2. Mobile Phase for Amino Acid Analysis 
The mobile phase was composed of Li-A，Li-B, Li-C, Li-R and ninhydrin reagent. 
Li-A, Li-B, Li-C and Li-R were stored at 4 °C until use. The ninhydrin reagent, a 
two-component reagent, was thorough mixing prior to use. The unmixed reagents 
were stored at room temperature in a cool, dry place, away from direct sunlight as 
suggested by the manufacturer. The mixed reagent being temperature sensitive was 
stored at 2 to 8 °C and under a nitrogen atmosphere prior to use. The safety 
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precautions as recommended by the company were followed. 
2.2.3. Reagents for RNA Extraction and Reverse Transcription-Polymerase 
Chain Reaction (RT-PCR) 
Sources of reagents used in RNA extraction were described in Table 2.1. TRIzol and 
isopropanol were stored at 4 while chloroform and ethanol were stored at room 
temperature until use. 
For reverse transcription (RT), deoxynucleotide mix (dNTP, 10 mM each dNTP), 
AMV reverse transcriptase (25 U尔 1), RNAse inhibitor (50 random primer 
p(dN)6 (2 i^g/ml), magnesium chloride (25 mM), nuclease-free water were used. 
Reagents used for polymerase chain reaction (PGR) included: deoxynucleotide mix 
(dNTP, 10 mM each dNTP), Tag DNA polymerase (produced in E. coli, 5 U/|dl) and 
sense and antisense primers. 
2.2.4. Sense and Antisense Primers 
PGR amplification of cDNA was performed using specific primers. Sense and 
antisense primers were designed using information obtained from GenBank Sequence 
Database. Table 2.2 showed the primers used for PGR in this study. 
Tris-ethylenediaminetetraacetic acid disodium salt (TE) buffer was used to 
reconstitute and dilute PGR primers. The TE buffer contained 10 mM Tris (pH 8.0) 
and 1 mM ethylenediaminetetraacetic acid disodium salt (EDTA). 
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cDNA Primer sequences (5，一 3') Nucleotide Amplified References 
Amplified position PCR 
fragment 
size (bp) 
P-actin Sense strand: 
TGAGACCTTCAACACCCCAG 2166-2185 201 Nudel et al., 1983 
Antisense strand: 
TTCATGAGGTAGTCTGTCAGGTCC 2343-2366 
SVCT2 Sense strand: 
CCGACAAAACCCTCTGGTTA 1794-1813 504 Accession number: 
AY004874 
Antisense strand: 
TCACCACCCACAACAGAAGA 2278-2297 
SVCTl Sense strand: 
GGGGTCCTAGGGATTACCAA 1185-1204 337 Accession number: 
NM_017315 
„ Antisense strand: _ 
TGGTCAGCAGCACAGTTAGG 1502-1521 
GLUTS Sense strand: 
. AAGAGCGGTTGGAAGACCTA 140-159 302 Accession number: 
- U17978 
Antisense strand: 
GGGAGACACCTCTCCAATGT 422-441 
Table 2.2 Primers used in RT-PCR and the predicted sizes of the PCR primers 
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2.2.5. Reagents for Electrophoresis 
6X DNA loading buffer contained 30 % (v/v) glycerol, 0.25 % (w/v) bromophenol 
blue and 36 mM EDTA (pH 8.5). 5X Tris-boric-EDTA (TBE) buffer was prepared 
by dissolving 54 g Tris base, 27.5 g boric acid and 3.72 g EDTA in 1 liter 
double-distilled water, and the pH was adjusted to 8.3. 
2.3. Animals 
Male BALB/c mice, aged 6-8 weeks (body weight 20-25 g), were randomly allocated 
to control and experimental groups and kept in cages in a room with a 12-h light:dark 
cycle, at a temperature of 25 °C, and at a constant humidity in the University Animal 
House. Throughout the experiments, the animals were fed a commercial diet (Glen 
Forrest Western, Australia) with the following composition: protein (18.9 %); fat (5.2 
%)； crude fiber (5 %); calcium (0.77 %); phosphorus (0.57 %); salt (0.41 %). 
“Supplemented with the following vitamins and minerals per kg: vitamin A (10000 lU); 
vitamin E (100 mg); vitamin B12 (30 mg); nicotinic acid (25 mg); folic acid (2 mg), 
thiamine (8 mg); pyridoxine (8 mg); copper (16 mg); magnesium (100 mg); selenium 
‘(0.1 mg); molybdenum (0.5 mg); vitamin D (2000 lU); vitamin K (2 mg); calcium 
pantothenate (20 mg); riboflavin (6 mg); biotin (100 mg); iodine (0.5 mg); iron (70 
mg); manganese (70 mg) and zinc (80 mg). The animals were given free access to 
water. Animals and feed were kindly provided by the Animal House of The Chinese 
University of Hong Kong. 
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2.4. Experimental Studies 
The six amino acids used in this study were methionine, homocysteine, I-cysteine, 
D-cysteine, taurine and leucine. The first five are sulfur-containing amino acids and 
leucine serves as a non-sulfur-containing amino acid control. All amino acids were 
prepared freshly by diluting with sterile normal saline and experimental animals 
received 100 mg/kg/d of one of the amino acids, while controls received same amount 
of normal saline by intraperitoneal injection for 1 day，7 days or 14 days, respectively. 
No abnormal behaviour or pathological signs were observed in treated mice. At the 
end of the treatment, all mice were killed by decapitation and blood was collected. 
The brain, liver, kidney, and heart were excised, rinsed briefly with cold phosphate 
buffered saline, weighed, frozen in liquid nitrogen and stored at - 80 °C until analysis. 
Again, no abnormalities, weight and appearance, were observed. The ascorbic acid 
and amino acid concentrations were analyzed by high performance liquid 
chromatography (HPLC) and amino acid analyzer, respectively. The vitamin C 
transporters gene expressions in various tissues were analyzed by RT-PCR. 
2.5. Methods 
2.5.1. Ascorbic Acid Analysis 
2.5.1.1. Extraction of Ascorbic Acid 
Blood obtained was placed in heparin-coated tubes and stood on ice until processing. 
Plasma was separated from blood cells by centrifugation at 10,000 rpm for 10 min at 
4 °C and stored at -80 °C until analysis. To extract ascorbic acid, equal volumes of 
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plasma and ice-cold 10 % (w/v) metaphosphoric acid (NaPOs) containing 0.54 mM 
Na2EDTA were mixed and centrifuged to remove the precipitated plasma proteins. 
The supernatant was stored at -80 °C until analysis. Upon thawing, samples were 
mixed with an equal volume of ice-cold 5 % (w/v) NaPOj containing 0.54 mM 
Na2EDTA plus 10 ^ig/ml isoascorbic acid (lA) which served as the internal standard. 
After dilution with cold 1.04 mM cysteine (Cys) containing 0.54 mM Na2EDTA, the 
vitamin C concentrations in plasma were analyzed by HPLC. This method is similar 
to that ofKutnink et al. (1987). 
Frozen tissue samples were homogenized in 50 mM perchloric acid (PA) by a 
Glas-Col homogenizer (Terre Haute, in USA) at 4 °C. The homogenates were 
centrifuged at 50,000 rpm for 30 min at 4 °C. After centrifugation, the supernatant 
was withdrawn, filtered through disposable 0.22 i^m disposable filters (Adventec MFS 
Inc.) and stored at -80 °C until analysis. Upon thawing, samples were diluted with 
50 mM PA and mixed with ice-cold 0.2 % (w/v) NaPOs containing 0.54 mM 
Na2EDTA, 1.04 mM Cys and 400 ng/ml IA and the vitamin C concentrations in 
tissues were analyzed by HPLC. This method is similar to that of Kutnink et al. 
(1987). 
2.5.1.2. Chromatography 
For ascorbic acid analysis, 20 \i\ aliquots were analyzed by HPLC. The 
chromatography system (Beckman System Gold) fitted with a 4.6 mm X 25 cm 
Beckman Ultrasphere octadecylsilyl (ODS) column. The detection system 
(Bioanalytical Systems Inc.) consisted of an LC4C amperometric controller and a 
thin-layer electrode cell containing a glassy-carbon working electrode, a stainless 
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Steel electrode top, and Ag/AgCl reference electrode. The applied potential was +0.5 
V (oxidative) with a sensitivity setting of 50 nA. The mobile phase was 40 mM 
sodium acetate, 0.54 mM NaaEDTA, 1.5 mM dodecyltriethylammonium phosphate 
and 7.5 % methanol, taken to pH 4.75 with glacial acetic acid. It was filtered 
through a 0.2 i^m filter (Micro Filtration Systems, Dublin, USA) prior to use. 
Ascorbic acid, as well as the internal standard, lA, was eluted at a flow rate of 0.5 
ml/min isocractically at ambient temperature. The retention times of ascorbic acid 
and isoascorbic acid were 15.02 and 16.45 min, respectively (Fig. 2.1). Ascorbic 
acid concentration in samples was calculated from a calibration curve generated from 
ascorbic acid/isoascorbic acid ratio in calibration samples. 
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2.5.2. Amino Acid Analysis 
2.5.2.1. Sample Preparation 
Blood obtained was placed in heparin-coated tubes. Plasma was separated from 
blood cells by centrifugation at 3,000 rpm for 15 min at 4 °C. An aliquot of 20 |il of 
50 % sulfosalicylic acid (SSA) was added to 200 [i\ of plasma and mixed thoroughly. 
The mixture was centrifuged at 13,300 rpm for 5 min at 4 °C. The clear supernatant 
was withdrawn, diluted with Li-S and analyzed by a Beckman amino acid analyzer. 
2.5.2.2. Chromatography 
For amino acid analysis, 20 \i\ aliquots were analyzed by a Beckman system gold 
HPLC amino acid analyzer. The Beckman system gold HPLC system includes a 
solvent module 126 AA, post column reactor 232, detector 166, autosampler 507, a 
0.4 X 10 cm stainless steel packed with spherical cation-exchange resin lithium 
column, and a computer work station. The mobile phase consisted of Li-A, Li-B, 
Li-C, Li-R and ninhydrin reagent. 
‘Using different buffers and temperatures as suggested by the manufacturer, a 
chromatographic profile of amino acid was obtained (Fig. 2.2). The abbreviations of 
amino acids and their retention times and the elution program were shown in Table 
2.3 and 2.4, respectively. 
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Amino Acid Abbreviation Retention Time (min) 
Phosphoserine PSER 2.36 
Taurine TAU 3.23 
Phosphoethanolamine PETN 3.66 
Urea UREA 5.35 
Aspartic acid ASP 10.68 
Hydroxyproline HYP 12.53 
Threonine THR 13.61 
Serine SER 14.84 
Glutamic acid GLU 19.27 
Sarcosine SAR 21.79 
a-Aminoadipic"acid AAD 23.14 
Proline PRO 27.54 
Glycine GLY 29.30 
Alanine ALA 31.30 
• Citrulline CIT 32.85 
a-Amino-/7-butyric acid ABU 35.34 
Valine VAL 38.77 
Cystine CYS 45.35 
Methionine MET 45.54 
Cystathionine �HCY 46.93 
Isoleucine ILE 47.69 
Leucine LEU 48.57 
Tyrosine TYR 50.22 
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Phenylalanine PHE 53.46 
P-Alanine BALA 61.01 
p-Aminoisobutyric acid BAB A 64.98 
Homocystine HCYS 68.51 
y-Aminoisobutyric acid GABA 76.97 
Ethanolamine ETN 87.00 
Ammonia NH3 92.12 
Hydroxylysine HYL 94.65 
fl//o-Hydroxylysine AHYL 95.04 
Ornithine ORN 101.21 
Lysine LYS 105.29 
1-Methylhistidine 1-MHIS 106.56 
Histidine ‘ HIS 108.92 
3-Methylhistidine 3-MHIS 112.37 
Anserine ANS 116.96 
Carnosine CARN 124.01 
’ Arginine ARG 135.82 
Table 2.3 Abbreviations of amino acids and their retention times 
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Time Flow rate Duration Buffer Ninhydrin Solvent Selections Column 
Pump (%) Pump Temperature 
(min) ^ (�C) 
Initial 0.500 — 67 33 Initial Settings 38 
11.00 70 
36.50 Li-Ato Li-B 
55.00 80 
77.00 Li-B to Li-C 
137.00 38 
138.00 Ninhydrin to H2O 
140.00 0.440 0.1 100 0 Li-C to Li-R 
Ninhydrin off 
142.00 Li-R to Li-A 
144.00 0.5 0.1 67 33 Ninhydrin on 
170.00 End 
Table 2.4 Elution program for amino acids 
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2.5.3. Determination of RNA Expression by RT-PCR Analysis 
The method as described by Huang et al. (1988) was followed and the steps are 
briefly stated below. 
2.5.3.1. RNA Isolation 
About 0.1 g of tissue samples was homogenized in 1 ml TRIzol reagent and 
centrifuged at 5,000 g for 5 min at 4 °C. The supernatant was transferred to a fresh 
tube and incubated at room temperature for 5 min. Afterwards, 0.2 ml chloroform 
was added to each tube and followed by vortexing for 15 sec. The tubes were 
allowed to stand at room temperature for 2-3 min and centrifuged at 11,900 g for 15 
min at 4 °C. The aqueous phase was transferred to a fresh tube. The RNA from the 
aqueous phase was precipitated by mixing with 0.5 ml isopropanol. The tubes were 
put into a freezer (-20 °C) overnight to ensure RNA extraction. Afterwards, the 
tubes were centrifuged at 11,900 g for 10 min at 4 °C and the supernatant removed. 
The RNA pellet was washed twice with 1 ml 75 % ethanol, mixed and centrifuged at 
7,500 g for 5 min at 4 °C. The supernatant was removed and the pellet was dried at 
room temperature. After drying, the pellet was dissolved in nuclease-free water and 
,stored at -20 °C until use. 
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2.5.3.2. Measurement of RNA Yield 
An aliquot of 4 \i\ RNA sample was mixed with 996 |il of autoclaved water for 
measuring the concentration of RNA at absorbance of 260 nm (A260) and the purity 
was determined by ratio of the absorbance of 260 nm to absorbance of 280 nm (A260/ 
A280). The pure RNA preparation should have an A260/ A280 value of 2.0. The yield 
and purity of RNA were calculated by the following equations: 
Yield = A260X 40/(4/1000) X 10^  
Purity = A260 / A280 
All RNA samples were adjusted to 0.5 ng/|al, and this RNA concentration was used 
for all reverse-transcript (RT) reactions. 
2.5.3.3. Reverse Transcription (RT) 
For RT reaction, 0.5 fig of total RNA was reverse-transcribed in a 20 \i\ reaction 
mixture containing 20 U of AMV reverse transcriptase, 5 mM MgCb, 1 mM of each 
dNTP, 40 U of RNAse inhibitor, 3.2 i^g random primer p(dN)6, 10 mM Tris/HCl, pH 
, 8 . 3 and 50 mM KCl. After thoroughly mixing, RT reaction was performed with a 
thermocycle polymerase chain reaction (PGR) machine (GeneAmp PCR System 9700, 
Perkin Elmer, U.S.A.). The conditions were 25 for 10 min; 42 °C for 60 min; the 
temperature was heated to 99 for 5 min and cooled to 4 for 5 min. At the end 
of the RT reaction, the cDNA formed was either stored in a freezer (-20 °C) until use, 
or PCR reaction was carried out immediately. 
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2.5.3.4. Polymerase Chain Reaction (PGR) 
The cDNA obtained from RT reaction was first undergone 2-fold dilution before the 
PGR. PGR was performed in a total volume of 25 fil consisting of 1.5 fil of RT 
sample, 0.625 U of Taq DNA polymerase, 1.5 mM MgCl2, 0.2 mM of each dNTP, 0.2 
|iM of both sense and antisense oligonucleotides, 10 mM Tris/HCl, pH 8.3 and 50 
mM KCl in a PGR machine (GeneAmp PGR system 9700，PerkinElmer, U.S.A.). 
The PGR conditions were 9 4 � C for 5 min, then 25 cycles of 94 for 0.5 min, 59 
for 1 min 15 sec for P-actin and SVCT2 (48 for 1 min for SVCTl; 58 °C for 1 min 
15 sec for GLUT3), 72 for 1 min, followed by final extension of 5 min at 72 
In all PCRs，25 to 35 cycles of reaction, depending on the amount of product formed, 
were carried out to ensure the resulted products were not saturated. The products 
were stored in a freezer until agarose gel electrophoresis. The specificities of the 
amplified products were checked as described before (Huang et al., 1988). 
2.5.3.5. Separation of PCR Products by Agarose Gel Electrophoresis 
A 5 |al-aliquot of PCR products was loaded with 6 X loading buffer and separated on a 
2 % (w/v) agarose gel. The gel was run in 0.5 X TBE buffer at 125 V for one hour 
and stained with 1 ng/ml ethidium bromide solution and photographed under UV 
fluorescence. 
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2.5.3.6. Quantification of Band Density 
Band density of the PCR product was quantified by densitometry using the 
ImageQuant program by Molecular Dynamics. The density of the band from the 
target gene being examined was first normalized by dividing by the corresponding 
band of the p-actin gene, and then the normalized value of the treated sample was 
divided by the normalized value of the corresponding control in the same set of 
treatment to obtain the relative density. The higher densitometry value suggested 
higher the gene expression was. 
2.6. Statistical Analysis 
Data were expressed as the arithmetic mean 土 standard error of the mean (SEM). 
The numbers of samples per experiment were listed in the text. Statistical 
differences between two experiment conditions were evaluated using the two-tailed 
Student t test with a p value of < 0.05 considered significant. 
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CHAPTERS RESULTS 
3.1. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic Acid 
Distributions in Mice 
Previous studies (see Section 1.3) showed that high levels of sulfur-containing amino 
acids are risk factors of heart diseases, renal diseases, liver cirrhosis as well as 
Alzheimer's disease. It is believed that they are harmful to our health by causing 
oxidation. On the other hand, ascorbic acid is an important water-soluble 
antioxidant. It is an agent that can scavenge many superoxides and other reactive 
oxygen species and moreover, protects against certain diseases. 
Form the above, phenomena, it is of considerable interest to understand whether this 
oxidation processes caused by sulfur-containing amino acids decrease the levels of 
antioxidants, such as vitamin C, in our body. Therefore, in the first part of this thesis 
project, the effects of sulfur-containing amino acids on vitamin C distribution in mice 
were examined. Since homocysteine is generated through the demethylation of 
methionine and largely catabolized to cysteine or remethylated to methionine and 
cysteine is further converted to taurine and other essential molecules, these amino 
acids were included in this study. Mice were assigned to receive methionine (Met) 
(100 mg/kg/d), homocysteine (Hey) (100 mg/kg/d), I-cysteine (I-Cys) (100 mg/kg/d), 
taurine (Tau) (100 mg/kg/d) and saline as control group (CTL) for 7 days. 
D-cysteine (D-Cys) (100 mg/kg/d) was included to determine if stereospecificity 
exists. In order to determine whether the changes on ascorbic acid status were 
limited to sulfur-containing amino acids, leucine (Leu) (100 mg/kg/d), which serves 
as a non-sulfur-containing amino acid control, was also investigated. These 
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concentrations were chosen as they have seen shown to cause various biological 
effects, but not the health of the animals, in previous studies (Garcia-Tevijano et al., 
2001; Kokkinakis et al., 1997). The vitamin C concentrations in the plasma, kidney, 
liver, brain, and heart were analyzed by HPLC as described in Section 2.5.1, 
3.1.1. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic 
Acid Concentrations in the Plasma 
Fig. 3.1 showed the effects of methionine, homocysteine,丄-cysteine，D-cysteine, 
taurine and leucine on ascorbic acid concentrations in the plasma. Ascorbic acid 
concentrations decreased significantly (p < 0.0001) in the plasma after 1 week 
treatment with methionine, homocysteine or cysteine. The reduction of ascorbic 
acid levels in the 丄-cysteine group (-26 %) was greater than that in D-cysteine group 
(-20 %). However, no significant difference in ascorbic acid concentration was 
observed in mice treated with taurine. It is noted that the ascorbic acid levels in the 
plasma were significantly decreased after receiving sulfur-containing amino acids, 
except taurine, whereas no significant change in ascorbic acid concentration was 
found in the leucine group. 
� 
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Fig. 3.1 Effects of sulfur-containing amino acids and leucine on ascorbic acid 
concentrations in the plasma. Male BALB/c mice were treated with 100 mg/kg/d 
of methionine (Met), homocysteine (Hey), L- and D-cysteine (Cys), taurine (Tau), 
leucine (Leu) or saline (CTL) for 7 days. The ascorbic acid levels were assessed as 
described in Materials and Methods. Results were expressed as means 土 SEM; N = 
16; */? < 0.0001 compared with the control. 
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3.1.2. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic 
Acid Concentrations in the Kidney 
The effects of methionine, homocysteine, L- and D-cysteine, taurine and leucine on 
ascorbic acid concentrations in the kidney were shown in Fig. 3.2. One-week 
treatment with methionine, homocysteine, L- or D-cysteine resulted in significant (p < 
0.001) lowering of ascorbic acid concentrations in the kidney. Among them, the 
reduction of ascorbic acid was the greatest after receiving methionine (-33 %). 
Comparing the effects of the two isomers of cysteine,丄-cysteine group (38.75 土 1.39 
|xg/g) had lower levels of ascorbic acid than that of Z)-cysteine group (46.69 土 1.67 
|ig/g). However, no significant change in ascorbic acid concentration was observed 
in mice treated with taurine. On the other side, the ascorbic acid concentration was 
significantly decreased by 18 % {p < 0.001) after administration of leucine. 
Comparing the effects between the sulfur-containing amino acids and leucine on 
ascorbic acid levels in the kidney, we observed that the reduction of ascorbic acid 
levels in the sulfur-containing amino acids groups, including methionine, 
homocysteine and I-cysteine, was greater than that after leucine treatment. 
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Fig. 3.2 Effects of sulfur-containing amino acids and leucine on ascorbic acid 
concentrations in the kidney. Male BALB/c mice were treated with 100 mg/kg/d 
of methionine (Met), homocysteine (Hey), L- and D-cysteine (Cys), taurine (Tau), 
leucine (Leu) or saline (CTL) for 7 days. The ascorbic acid levels were assessed as 
described in Materials and Methods. Results were expressed as means 土 SEM; N = 
16; < 0.001 compared with the control. 
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3.1.3. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic Acid 
Concentrations in the Liver 
The effects of methionine, homocysteine, L- and D-cysteine, taurine and leucine on 
ascorbic acid concentrations in the liver were shown in Fig. 3.3. Ascorbic acid 
concentrations decreased significantly (p < 0.05) in liver after 1-week treatment with 
methionine or homocysteine. Concerning the two isomers of cysteine, the ascorbic 
acid concentrations in the liver were significantly decreased by 13 % {p < 0.05) after 
L-cysteine treatment, while that in D-cysteine group showed insignificant change. 
No significant difference in ascorbic acid content was observed in the taurine group. 
It is noted that both sulfur-containing amino acids, including methionine, 
homocysteine and /^-cysteine, as well as non-sulfur-containing amino acid, leucine, 
resulted in significant {p < 0.05) lowering of ascorbic acid concentrations in the liver. 
It can be seen that methionine and leucine showed similar change on vitamin C levels, 
while the reduction of ascorbic acid levels was greater in the leucine group (-26 %) 
than that after homocysteine (-13 %) and I-cysteine (-13 %) treatment. 
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Fig. 3.3 Effects of sulfur-containing amino acids and leucine on ascorbic acid 
concentrations in the liver. Male BALB/c mice were treated with 100 mg/kg/d of 
methionine (Met), homocysteine (Hey), L- and /^-cysteine (Cys), taurine (Tau), 
leucine (Leu) or saline (CTL) for 7 days. The ascorbic acid levels were assessed as 
described in Materials and Methods. Results were expressed as means 土 SEM; N = 
16; < 0.05 compared with the control. 
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3.1.4. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic Acid 
Concentrations in the Brain 
Fig. 3.4 showed the effects of methionine, homocysteine, I-cysteine, Z)-cysteine, 
taurine and leucine on ascorbic acid concentrations in the brain. One-week 
treatment with homocysteine or taurine resulted in significant {p < 0.05) elevation of 
ascorbic acid concentrations in the brain. After administration of I-cysteine, the 
ascorbic acid concentration in the brain was significantly increased by 12 % {p < 
0.0001), whereas the Z)-cysteine group showed no significant change. In contrast, a 
significant decrease {p < 0.005) in ascorbic acid concentration was observed in mice 
administered with methionine. After receiving leucine, the ascorbic acid 
concentration was significantly decreased by 7 % (p < 0.005). It can be seen that 
both sulfur-containing amino acids and leucine had significant effects on ascorbic acid 
concentrations in the brain. 
� 
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Fig. 3.4 Effects of sulfur-containing amino acids and leucine on ascorbic acid 
concentrations in the brain. Male BALB/c mice were treated with 100 mg/kg/d of 
methionine (Met), homocysteine (Hey), L- and Z)-cysteine (Cys), taurine (Tau), 
leucine (Leu) or saline (CTL) for 7 days. The ascorbic acid levels were assessed as 
described in Materials and Methods. Results were expressed as means 土 SEM; N = 
16; 0.05 compared with the control. 
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3.1.5. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic Acid 
Concentrations in the Heart 
Fig. 3.5 showed the effects of methionine, homocysteine, I-cysteine, D-cysteine, 
taurine and leucine on ascorbic acid concentrations in the heart. We observed that 
neither sulfur-containing amino acids: methionine, homocysteine, cysteine and taurine 
nor non-sulfur-containing amino acid, leucine, had significant changes in ascorbic 
acid concentrations in the heart. Although there were no significant changes, the 
general trend of ascorbic acid concentrations was decreased. A decrease in vitamin 
C levels may be associated with heart disease caused by sulfur-containing amino acids, 
such as homocysteine and cysteine. 
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Fig. 3.5 Effects of sulfur-containing amino acids and leucine on ascorbic acid 
concentrations in the heart. Male BALB/c mice were treated with 100 mg/kg/d of 
methionine (Met), homocysteine (Hey), L- and /^-cysteine (Cys), taurine (Tau), 
leucine (Leu) or saline (CTL) for 7 days. The ascorbic acid levels were assessed as 
described in Materials and Methods. Results were expressed as means 土 SEM; N = 
16. 
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3.1.6. Summary 
Form the above results, it is clear that 1 -week administration of sulfur-containing 
amino acids had significant effects on vitamin C distributions in mice. After 
administration of methionine, homocysteine and Z-cysteine, there was significantly 
decreased in ascorbic acid concentrations in the plasma, kidney and liver. In the 
brain, the ascorbic acid concentration was significantly increased after homocysteine, 
Z-cysteine and taurine treatment, while a significant decrease was observed in the 
methionine group. It is noted that the sulflir-containing amino acids caused 
significant changes in ascorbic acid concentrations in the kidney, liver and brain, 
whereas they showed no significant changes in ascorbic acid levels in the heart. 
This suggests tissue specificity might exist. 
Concerning the two isomers of cysteine, L- and D-cysteine had different effects on 
vitamin C distribution in mice. Z-cysteine significantly increased ascorbic acid 
levels in the brain, while D-cysteine did not. In the liver, the ascorbic acid 
concentration was significantly decreased after receiving 丄-cysteine but no significant 
change was observed following D-cysteine treatment. The reduction of ascorbic 
acid level in I-cysteine group was greater than that receiving D-cysteine in both 
plasma and kidney. This suggests that stereospecificity might exist. 
After 1-week administration of leucine, the ascorbic acid concentrations decreased 
significantly in the kidney, liver and brain, while no significant changes were found in 
the plasma and heart. These suggest that leucine, a non-sulfur-containing amino acid, 
can also affect the vitamin C distributions in mice and the changes on ascorbic acid 
status is not limited to sulfur-containing amino acids . 
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3.2. Time-Response 
Results described in Section 3.1 showed that 1-week administration of methionine, 
homocysteine, L- and D-cysteine, taurine and leucine had significant effects on 
vitamin C distribution in mice. The ascorbic acid concentrations in the plasma were 
significantly decreased after receiving methionine, homocysteine and cysteine. 
After administration of methionine, homocysteine, Z-cysteine and leucine, the 
ascorbic acid concentrations were significantly decreased in both liver and kidney. 
In the brain, the ascorbic acid level was significantly increased by homocysteine, 
L-cysteine and taurine treatment, while a significant decrease was observed after 
administration of methionine and leucine. 
In order to investigate the effects of amino acids on vitamin C levels in a relative 
shorter and longer period of time, mice were assigned to receive 100 mg/kg/d of 
methionine, homocysteine, L- and D-cysteine, taurine, leucine or saline as control 
group for 1 day or 14 days. The ascorbic acid concentrations in the plasma, kidney, 
liver, brain and heart were analyzed by HPLC. 
� 
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3.2.1. Effects of Sulfur-Containing Amino Acids and Leucine Administration 
for Various Periods on Ascorbic Acid Concentrations in the Plasma 
Fig. 3.6 showed the effects of sulfur-containing amino acids and leucine injection for 
1-14 days on ascorbic acid concentrations in the plasma. After 1-day injection of 
methionine, homocysteine and I-cysteine, the ascorbic acid concentrations were 
significantly decreased by 10 % {p < 0.05), 17 % {p < 0.001) and 17 % {p < 0.005), 
respectively. The ascorbic acid levels were further declined following 7 days 
treatment. After 7-day administration of methionine, homocysteine and I-cysteine, 
the ascorbic acid concentrations were significantly decreased by 16 % {p < 0.0001)， 
24 % {p < 0.0001) and 26 % (p < 0.0001)，respectively. The level of ascorbic acid in 
the plasma was not modified by prolonging the treatment to 14 days. 
The ascorbic acid concentration decreased significantly by 12 % (p < 0.05) in the 
plasma after 1-day D-cysteine treatment. The reduction of ascorbic acid 
concentrations was greater following 7-day treatment in which a significant decrease 
by 20 o/o (p < 0.0001) was observed. The degree of reduction in ascorbic acid levels 
for 7-day and 14-day treatment was similar, a significant decrease by 19 % (p < 
0.0005) was observed at day 14. 
For taurine, the ascorbic acid concentration was significantly decreased by 12 % (p < 
0.05) after 1-day injection, while no significant changes were observed at day 7 and 
14. Besides, no differences in ascorbic acid concentration were found in the leucine 
group throughout the study period. 
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Fig. 3.6 Effects of sulfur-containing amino acids and leucine administration for 
various periods on ascorbic acid concentrations in the plasma. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 1 day, 7 days or 14 
days. The ascorbic acid levels were assessed as described in Materials and Methods. 
Results were expressed as means 士 SEM; N = 16; * p < 0.05 compared with the 
corresponding control. 
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3.2.2. Effects of Sulfur-Containing Amino Acids and Leucine Administration for 
Various Periods on Ascorbic Acid Concentrations in the Kidney 
Fig. 3.7 showed the effects of sulfur-containing amino acids and leucine 
administration for various periods on ascorbic acid concentrations in the kidney. 
After 1-day injection of methionine, homocysteine, Z-cysteine and D-cysteine, the 
ascorbic acid concentrations were significantly decreased by 21 % (p < 0.0001)，21% 
(p < 0.0001), 13 % (p < 0.005) and 13 % (p < 0.005), respectively. The ascorbic 
concentration was further declined following 7-day treatments. After 7 days 
administration of methionine, homocysteine, I-cysteine and D-cysteine, the ascorbic 
acid concentrations were significantly decreased by 33 % (p < 0.0001), 24 % (p < 
0.0001)，30 % (p < 0.0001) and 16 % (p < 0.0005), respectively. At day-14, 
significantly decreased of ascorbic acid concentrations were also observed but the 
degrees of reduction were smaller. The concentrations were significantly decreased 
by 17 % (p < 0.005), 11 % (p < 0.05), 15 % (p <0.05) and 12 % (p < 0.05), 
respectively. 
The ascorbic acid concentration decreased significantly (p < 0.05) in the kidney after 
1-day and 14-day treatment with taurine, while no change was observed at day-7. 
,For leucine, no significant change in ascorbic acid concentration was observed at 
day-1, but a significant decrease was found at day-7 and day-14. The ascorbic acid 
concentration was significantly declined by 18 % (p < 0.005) and 9 % (p <0.05) at 
day-7 and day-14, respectively. 
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Fig. 3.7 Effects of sulfur-containing amino acids and leucine administration for 
various periods on ascorbic acid concentrations in the kidney. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 1 day, 7 days or 14 
days. The ascorbic acid levels were assessed as described in Materials and Methods. 
Results were expressed as means 土 SEM; N = 16; * p < 0.05 compared with the 
corresponding control. 70 
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3.2.3. Effects of Sulfur-Containing Amino Acids and Leucine Administration for 
Various Periods on Ascorbic Acid Concentrations in the Liver 
The effects of sulfur-containing amino acids and leucine injection for 1-14 days on 
ascorbic acid concentrations in the liver were shown in Fig. 3.8. After 1 day 
administration of methionine and leucine, the ascorbic acid concentrations were 
significantly decreased by 21 % (p < 0.0001) and 23 % (p < 0.0001), respectively. 
The ascorbic acid levels were further declined with 7 days treatment. The ascorbic 
acid concentrations were significantly decreased by 24 % (p < 0.001) and 28 % {p < 
0.0001)，respectively. At day 14，a significant decrease in ascorbic acid 
concentrations was also observed, though the reduction in ascorbic acid levels was 
smaller. Following 14-day administration of methionine and leucine, the ascorbic 
acid concentrations were significantly decreased by 9 % (p < 0.05) and 17 % (p < 
0.001)，respectively. For taurine, the ascorbic acid concentration level was 
significantly decreased by 14 % (p < 0.01) at day-1, while no significant change was 
observed afterwards. 
After 1 day, 7 days and 14 days administration of homocysteine, the ascorbic acid 
concentration was significantly decreased by 21 % (p < 0.001), 13 % (p <0.05) and 9 
' % ( p < 0.05), respectively. This suggests that the effect of homocysteine on ascorbic 
acid concentration in liver is inversely time-dependent. 
Similarly, the effect of L-cysteine on ascorbic acid levels is also time-dependent. 
The ascorbic acid concentrations following 1 day, 7 days and 14 days treatment were 
decreased by 10 % (p < 0.05), 13 % (p < 0.05) and 15 % (p < 0.05), respectively. 
For D-cysteine, no significant changes were observed throughout the study period. 
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Fig. 3.8 Effects of sulfur-containing amino acids and leucine administration for 
various periods on ascorbic acid concentrations in the liver. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 1 day, 7 days or 14 
days. The ascorbic acid levels were assessed as described in Materials and Methods. 
Results were expressed as means 土 SEM; N = \6\ * p < 0.05 compared with the 
corresponding control. 
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3.2.4. Effects of Sulfur-Containing Amino Acids and Leucine Administration for 
Various Periods on Ascorbic Acid Concentrations in the Brain 
Fig. 3.9 showed the effects of sulfur-containing amino acids and leucine 
administration for various periods on ascorbic acid concentrations in the brain. After 
1 day treatment with methionine, the ascorbic acid concentration was significantly 
decreased by 21 % {p < 0.0001). The ascorbic acid concentration was also declined 
following 7-day treatment but the decrease was smaller (-5 %), while no significant 
change in ascorbic acid concentration was found at day-14. 
After 1 day administration of homocysteine,丄-cysteine and taurine, no significant 
changes in ascorbic acid concentrations were observed. The ascorbic acid 
concentration increased significantly (p < 0.05) in the brain following 7 days 
treatment with the above amino acids. After this period, the level of ascorbic acid in 
brain was not modified. For D-cysteine, no significant differences in ascorbic acid 
level were observed throughout the study period. One of the possible reasons is that 
Jhis amino acid cannot enter the brain significantly. 
There was no significant change in ascorbic acid concentration after 1 day 
administration of leucine. A significant decrease (-7 %) in ascorbic acid 
concentration was found at day-7 and the ascorbic acid level was further decreased 
following 14 days treatments in which a decrease of 13 % (p < 0.001) was observed. 
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3.2.5. Effects of Sulfur-Containing Amino Acids and Leucine Administration for 
Various Periods on Ascorbic Acid Concentrations in the Heart 
Fig. 3.10 showed the effects of sulfur-containing amino acids and leucine 
administration for various periods on ascorbic acid concentrations in the heart. After 
receiving methionine, homocysteine, cysteine and leucine, no significant changes in 
ascorbic acid concentrations were observed throughout the study period. 
After 1 day injection of taurine, the ascorbic acid concentration was significantly 
increased by 33 % (p < 0.001). No significant changes in ascorbic acid were 
observed at day-7 and day-14. 
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Fig. 3.10 Effects of sulfur-containing amino acids and leucine administration for 
various periods on ascorbic acid concentrations in the heart. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 1 day，7 days or 14 
days. The ascorbic acid levels were assessed as described in Materials and Methods. 
Results were expressed as means 土 SEM; N= 16. * p< 0.001 compared with the 
corresponding control. 
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3.2.6. Summary 
From the above results, in general, greater changes in ascorbic acid levels in the 
plasma and tissues, except the heart, were observed at day-7 when compared with 
day-1. A further decline in ascorbic acid levels were found at day-7 in the plasma, 
kidney and liver. In the brain, a significant increase in ascorbic concentrations was 
observed after 7 days administration of homocysteine, I-cysteine and taurine, while 
they showed no significant changes at day-1. Following 14 days of treatment, a 
significant decrease in ascorbic acid concentrations in the kidney and liver was also 
observed, though the reduction of ascorbic acid was smaller than those at day-7, and 
no significant changes in ascorbic acid status were observed in the plasma, brain and 
heart. It is noted that a significant decrease in ascorbic acid levels in the kidney and 
liver was observed after 1 day and 14 days treatment with sulfur-containing amino 
acids and leucine. These suggest that both sulfur-containing amino acids and leucine 
have significant effects on vitamin C levels in a relatively shorter and longer 
treatment period. 
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3.3. Effects of Sulfur-Containing Amino Acids and Leucine on SVCT and 
GLUT3 Gene Expressions 
Cellular ascorbic acid accumulation occurs through two facilitated transport 
mechanisms: either by direct uptake of ascorbic acid, or by uptake of dehydroascorbic 
acid, and followed by intracellular reduction to ascorbic acid (Diliberto et al, 1983; 
Rumsey et al., 1997). Two isoforms of sodium-dependent vitamin C transport 
protein (SVCT) mediate direct ascorbic acid transport, named SVCTl and 2, have 
recently been isolated from the rat (Tsukaguchi et al., 1999). SVCTl is predominant 
in the liver and kidney and SVCT2 is found in the brain and heart (Wang et al., 1999). 
In the brain, dehydroascorbic acid is taken up using the glucose transporters (GLUTl 
and 3), and upon transport into the brain, dehydroascorbic acid is reduced to ascorbic 
acid (Aller et al., 1997; Rumsey et al., 1997). 
Results in Sections 3.1 and 3.2 showed that administration of 100 mg/kg/d 
sulfur-containing amino acids and leucine altered ascorbic acid concentrations in 
plasma and tissues, including the kidney, liver and brain. However, the mechanism 
remains unknown. In the present study, we attempted to see whether the 
sulfur-containing amino acids and leucine would affect the expression of SVCTl, 
SVCT2 and GLUT3 genes in mice. Mice were treated with 100 mg/kg/d of 
methionine, homocysteine, L- and D-cysteine, taurine, leucine or saline (control) for 7 
days or 14 days, and the levels of SVCTl, SVCT2 and GLUT3 mRNAs in various 
tissues, including the kidney, liver, brain and heart, were semi-quantified by RT-PCR. 
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3.3.1. Effects of Sulfur-Containing Amino Acids and Leucine Administration on 
SVCT mRNA Expression in the Kidney 
Experiments described in Section 3.2.2 demonstrated that administration of high 
concentrations of sulfur-containing amino acids and leucine significantly decreased 
the ascorbic acid concentrations in the kidney, it is of interest to determine if the 
changes in ascorbic acid levels were due to the reduction of one, or both, isoforms of 
SVCT; thus SVCT mRNA levels were determined from total RNA isolates of treated 
kidney homogenates by RT-PCR. Using primers specific for SVCTl and SVCT2, 
single-band products of 337 and 504 bp, respectively, which corresponded to the 
predicted sizes based on published mRNA sequences, were observed. The mRNA 
levels of both SVCTl and SVCT2 in treated mice kidney were determined and 
assessed relative to levels of p-actin (201 bp) in the same samples. 
Results showed that there was a significant decline in SVCTl mRNA levels after 
receiving Met, Hey and 丄-Cys for 7 days, while no significant changes were observed 
with other treatments (Fig. 3.11). On the other hand, SVCT2 mRNA levels 
decreased significantly after 7 days administration of 丄-Cys and Leu, and no 
significant changes were observed with other treatments (Fig. 3.12). Following 14 
days administration of L-Cys, there was a significant decline in both SVCTl and 
SVCT2 mRNA levels, while administration of Met showed a significant decrease only 
in SVCTl mRNA levels (Figs. 3.13 & 3,14). 
The above results suggest that decrease in SVCT levels may occur after receiving 
high concentrations of sulfur-containing amino acids and leucine, which could be one 
of the explanations responsible for the decline in ascorbic acid concentrations in the 
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kidney. However, the mechanism involved remains to be determined. 
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Fig. 3.11 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on SVCTl and p-actin mRNA levels in the kidney. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the kidney was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 士 SEM of the ratios of SVCTl to P-actin; " = 3; * p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.11 A. 
81 
Chapter 3 Results 
CTL Met Hey 
M I — I r 1 I ‘ 
SVCTl b b b b B B B B " " " 
1 0.92 0.93 0.83 0.79 0.79 0.79 0.75 0.72 
p-actin m j j U j j j j j m m m m u m 201 
CTL D-Cys L-Cys 
SVCTl 337 bp 
1 0.97 1.03 0.94 0.96 0.81 0.79 0.74 0.77 
P-actin 201 bp 
CTL Tau 
M I I 1 
SVCTl ^ ^ ^ H S ^ ^ ^ ^ J ^ Q i B H B H H i l M B I H I 
1 0.94 0.94 1.02 0.98 0.93 
CTL Leu 
SVCTl 337 bp 
1 1.05 0.89 1.01 0.89 0.88 
p_actiii l ^ i m J ^ ^ Q J ^ J Q ^ J l ^ ^ ^ m J j ^ U Q l 201 
Fig. 3.11A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on SVCTl and p-actin mRNA levels in the kidney. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the kidney was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCTl and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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Fig. 3.12 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on SVCT2 and p-actin mRNA levels in the kidney. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the kidney was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 士 SEM of the ratios of SVCTl to P-actin; N=3;*p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.12 A. 
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SVCT2 i^^oymimmmiQmmjj j j i 504 bp 
1 0.97 0.92 0.87 0.88 0.75 0.83 0.73 0.76 
P-actin 201 bp 
M CTL Tau 
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SVCT2 504 bp 
1 0.90 0.94 0.98 0.93 0.91 
P-actin 201 bp 
CTL Leu 
M 丨 丨 丨 I 
^ 1 1.02 1 0.75 0.78 0.71 
Fig. 3.12A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on SVCT2 and P-actin mRNA levels in the kidney. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the kidney was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PGR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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Fig. 3.13. Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCTl and p-actin mRNA levels in the kidney. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the kidney was isolated and subjected to RT-PCR as described in 
Chapter 2. Results were expressed as means 士 SEM of the ratios of SVCTl to 
P-actin; N = 3; * p < 0.05 compared with the control. Gel data are shown in Fig. 
3.13A. 
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Fig. 3.13A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCTl and p-actin mRNA levels in the kidney. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the kidney was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCTl and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); iV = 3 for all 
experiments. 
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Fig. 3.14 Effects of administration of sulfur-containing amino acids and leucine 
for 14 days on SVCT2 and p-actin mRNA levels in the kidney. Male BALB/c 
mice-were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 days. Total 
RNA in the kidney was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of SVCT2 to P-actin; p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.14A. 
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CTL Met Hey 
SVCT2 504 bp 
1 1.03 1.27 1.02 1.12 0.80 0.95 1.24 1.17 
炒-actin 謝 bp 
CTL D-Cys L-Cys 
M I 1 I 1 I 1 
SVCT2 504 bp 
1 1.08 1.02 0.97 1.05 0.95 0.72 0.81 0.83 
P-actin 201 bp 
CTL Tau Leu 
M , 1 I 丨 I 1 
SVCT2 504 bp 
1 1.22 1.08 1.26 1.01 1.06 0.90 1.01 0.96 
P-actin 201 
Fig. 3.14A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCT2 and p-actin mRNA levels in the kidney. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the kidney was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and P-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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3.3.2. Effects of Sulfur-Containing Amino Acids and Leucine Administration on 
SVCT mRNA Expression in the Liver 
As described in Section 3.2.3, administration of high concentrations of methionine, 
homocysteine, L-cysteine and leucine for 7 and 14 days significantly decreased the 
ascorbic acid concentrations in the liver, we attempted to see whether the decrease in 
ascorbic acid levels were due to the decrease of one, or both, isoforms of SVCT, thus 
SVCT mRNA levels were determined from total RNA isolates of treated liver 
homogenates using RT-PCR. 
Both SVCTl and SVCT2 mRNA levels were decreased significantly after receiving 
methionine and leucine for 7 days. The ratio of SVCTl :p-actin mRNA levels 
declined by 37 % and 51 %, respectively (Fig. 3.15), while that in SVCT2 decreased 
by 44 % and 51 %, respectively (Fig. 3.16). After administration of homocysteine 
for 7 days, a significant decrease (-24 %) in SVCT2 mRNA levels was also observed 
(Fig. 3.16). 
Following 14 days of administration of methionine and leucine, there was a 
significant decline in SVCTl mRNA levels (Fig. 3.17). In contrast, SVCT2 mRNA 
levels showed no significant change after receiving either treatment (Fig. 3.18). The 
latter is in line with previous report that SVCT2 is mainly expressed in the brain and 
retina (Wang et al., 1999). The above results suggest that sodium-dependent 
ascorbic acid transport decline after receiving high concentrations of methionine, 
homocysteine and leucine, which may account for the reduction in liver ascorbic acid 
content. 
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Fig. 3.15 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on SVCTl and p-actin mRNA levels in the liver. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the liver was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 士 SEM of the ratios of SVCTl to P-actin; N=3;* p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.15 A. 
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CTL Met Hey 
M I 1 I I I I 
SVC. ^ b b h b s b ^ 
1 1.03 0.91 0.71 0.56 0.55 1.09 1.01 0.89 
P-actin i m g m m j u m j j j ^ j j u j j m j 201 bp 
CTL D-Cys L-Cys 
j j j ^ ^ j m j m j u j j j j j j j j j m j j j j ^ j j j j j j j ^ j j j ^ j u j j m u 33? 
1 1.07 1.04 0.95 1.12 1.13 1.02 1.05 1.01 
P-actin 201 
A/f CTL Tau 
M , , � n I I 
^ ^ ^ S H H H ^ I ^ H H I H ^ H ^ H H H H H 
SVCTl ^ ^ ^ g g g g j ^ g g g H g ^ ^ ^ y ^ H 337 bp 
1 0.89 1.15 1.01 1.03 0.87 
炒-ac如 加 bp 
CTL Leu 
M 丨 丨 丨 I 
SVCTl n ^ m m ^ m i i i i i i j m i i i m m i ^ ^ 33? bp 
“ 1 1.02 1.07 0.56 0.41 0.52 
P-actin m m m j j j j j u m i j m g ^ ^ g j ^ Q m 201 bp 
Fig. 3.15A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on SVCTl and p-actin mRNA levels in the liver. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the liver was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCTl and P-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); TV = 3 for all 
experiments. 
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Fig. 3.16 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on SVCT2 and p-actin mRNA levels in the liver. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the liver was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of SVCT2 to p-actin; N=3;* p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.16A. 
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CTL Met Hey 
^ ^ ^ i i i i i i i i a i i i i i i 
SVCT2 504 bp 
1 0.92 1.04 0.61 0.49 0.54 0.78 0.79 0.72 
P-actin i m m ^ ^ j g j j m j j u j j j j j ^ j 201 bp 
CTL D-Cys L-Cys 
M I 1 I 1 I 1 
s v c n 
1 1.01 1.06 0.82 0.92 1.08 1.14 0.95 1.08 
p a �n i m ^ ^ j m j Q ^ Q j ^ Q j j j i i i ^ u m ^ m ^ u Q Q i Q i Q j 201 
CTL Tau 
M . • • ^ 
SVCT2 m B ^ m ^ ^ B B ^ ^ ^ s bp 
1 0.96 1.02 1.12 1.21 1 
CTL Leu 
M 丨 丨 丨 丄 
, 1 0.92 1.03 0.37 0.64 0.43 
p_actin m m m ^ ^ ^ n ^ Q ^ j ^ ^ Q j m j j 201 
Fig. 3.I6A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on SVCT2 and p-actin mRNA levels in the liver. Male 
BALB/C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the liver was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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Fig. 3.17. Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCTl and f-actin mRNA levels in the liver. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the liver was isolated and subjected to RT-PCR as described in 
Chapter 2. Results were expressed as means 士 SEM of the ratios of SVCTl to 
P-actin; N=3;* p < 0.05 compared with the control. Gel data are shown in Fig. 
3.17A. 
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CTL Met Hey 
SVCTl 
1 0.95 1.07 0.76 0.79 0.82 0.85 1.01 0.79 
P-actin m u j j m ^ j j j m j j j j j m j 201 
CTL Z)-Cys L-Cys 
SVCTl 337 bp 
1 0.88 1 0.96 1.10 1.18 0.91 1.02 0.84 
CTL Tau Leu 
SVCTl ^ B H H H H H H I H H R I 3 3 7 bp 
1 0.87 0.97 0.92 0.87 0.76 0.82 0.80 0.72 
P-actin ^ m g j o m ^ g j m o ^ j 201 
Fig. 3.17A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCTl and f-actin mRNA levels in the liver. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the liver was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCTl and P-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); iV = 3 for all 
experiments. 
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Fig. 3.18 Effects of administration of sulfur-containing amino acids and leucine 
for 14 days on SVCT2 and p-actin mRNA levels in the liver. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 days. Total 
RNA in the liver was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of SVCT2 to P-actin; N = ?>. 
Gel data are shown in Fig. 3.18A. 
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CTL Met Hey 
M I 1 I 1 I 1 
SVCT2 504 bp 
1 1.20 0.89 0.89 0.94 0.96 0.82 0.91 0.67 
M CTL D-Cys L-Cys 
SVCT2 | ^ | 2 9 H B 9 B S E 9 H B 3 E 3 H 504 bp 
1 0.98 0.85 0.81 0.89 084 0.82 0.94 0.87 
P-actin 201 bp 
CTL Tau Leu 
M I 1 I 1 I 1 
SVCT2 504 bp 
1 0.93 1.04 0.94 1.11 1.10 0.97 0.94 0.84 
P-actin 201 bp 
Fig. 3.18A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCTl and p-actin mRNA levels in the liver. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and Z)-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the liver was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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3.33. Effects of Sulfur-Containing Amino Acids and Leucine Administration on 
SVCT and GLUT3 mRNA Expression in the Brain 
Vitamin C is transported into the brain via two mechanisms: one mechanism involves 
the efficient transport of dehydroascorbic acid, through glucose transporters (GLUTl 
& GLUT3) by an energy-independent facilitative process, and the other involves the 
SVCT. Experiments described in Section 3.2.4 demonstrated that administration of 
high concentrations of homocysteine, L-cysteine and taurine for 7 days significantly 
increased the ascorbic acid concentrations in the brain, while no significant changes 
were observed following 14 days treatments. On the other hand, the ascorbic acid 
concentration was significantly declined after 7 and 14 days injection with leucine. 
To determine whether the changes in ascorbic acid levels were due to the changes of 
SVCT and GLUT, their mRNA levels were determined from total RNA isolates of 
treated brain homogenates using RT-PCR. 
Results showed that after receiving homocysteine and I-cysteine for 7 days, the 
-GLUT3 mRNA levels were significantly increased by 24 % and 36 %, respectively 
(Fig. 3.19). In contrast, SVCT2 mRNA levels showed no significant changes after 
the above treatments (Fig. 3.20). The above results suggest that an increase in 
GLUT-3 levels after receiving high concentrations of homocysteine and 丄-cysteine 
may be responsible for the elevation in ascorbic acid concentrations in the brain. 
Following 14 days injection, no significant changes were observed in both GLUT3 
and SVCT2 expressions (Figs. 3.21 & 3.22). 
After 7 days administration of taurine, the ascorbic acid concentration was increased 
significantly, while no significant changes in ascorbate transporters, SVCT or GLUT3, 
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were observed in the brain. These suggest that the increased ascorbic acid 
concentration by taurine in the brain is not related to the ascorbate transporters 
mechanism. 
After administration of leucine for 7 days and 14 days, a significant decrease of 45 % 
and 25 % in SVCT2 mRNA levels was observed, respectively (Figs. 3.20 and 3.22). 
The decline in SVCT2 mRNA levels during leucine treatment may account for the 
decrease in the brain ascorbic acid content. In contrast, no amplification product of 
SVCTl was observed in the brain (Fig. 3.23) which supports previous finding that 
brain is devoid of detectable SVCTl-specific transcript (Wang et al., 1999). 
� 
, 99 
Chapter 3 Results 
1 . 6 — 
1.4 : _ 
1.2 - …•• 
O 藝 p 
i'nI Mi^  
r . . . i I I I r M 
p o . 6 i i 'V ^ i 
• ^  I H ^ 口 
^ ^ -y： q ,‘ 
. � o J - i J l - i B 丨 
CTL Met Hey D-Cys L-Cys Tau Leu 
Treatment 
Fig. 3.19 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on GLUT3 and p-actin mRNA levels in the brain. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the brain was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of GLUT3 to P-actin; N=3;* p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.19 A. 
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CTL Met Hey 
M I 1 I ~ ~ 丨 丨 1 
GLUT3 302 bp 
1 1.04 0.93 0.92 0.97 1.04 1.24 1.23 1.26 
P-actin m j j g g m j g j m j j j j j j j j u g j u u j lo ibp 
CTL D-Cys L-Cys 
M . — — • • — — • • — — ‘ 
GLUT3 302 bp 
1 0.99 1.03 1.06 1.12 1.31 1.34 1.41 1.32 
P-actin m m ^ Q o m ^ Q o m m m 201 bp 
CTL Tau 
M 丨 丨 丨 I 
GLUT3 302 bp 
1 0.96 0.99 1.03 1.03 0.99 
P-actin m O U J J J J I Q m ^ E S E S I 201 bp 
CTL Leu 
M l n I ~ ~ I 
GLUT3 302 bp 
1 1.04 0.85 0.95 0.82 0.83 
Metin m m o g m g u n u j 201 bp 
Fig. 3.19A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on GLUTS and p-actin mRNA levels in the brain. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the brain was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of GLUTS and P-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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Fig. 3.20 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on SVCT2 and p-actin mRNA levels in the brain. Male BALB/c mice 
were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the brain was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 士 SEM of the ratios of SVCT2 to P-actin; N=3\* p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.20A. 
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CTL Met Hey 
M I 1 I j 丨 I 
SVCT2 ^ifj^^/jjjjj/jjjjjjfjj/jSjlBSBBBSBBBSL 504 bp 
1 0.92 0.94 0.97 1.05 0.85 0.99 1.07 0.95 
P-actin — P U P i i i ^ 曙 服 • • I••暨 _ J L J 1 
201bp 
CTL /)-Cys ^-Cys 
M I • • 1 ‘ • -
SVCT2 504 bp 
1 0.90 0.97 0.93 0.67 0.96 1.03 0.95 0.84 
201bp 
CTL Tau 
M 丨 丨 I 1 
SVCT2 |^m[|2BB9B9B9B9B9l 504 bp 
1 1.02 0.94 0.93 1.03 1 
p-actin 
CTL Leu 
M r 丨 丨 — 
SVCT2 SB9BB3BB3B 504bp 
^ 1 0.87 0.98 0.54 0.63 0.48 
P-actin i m i l l ^ ^ l Q ^ ^ ^ J I ^ ^ I I j j ^ J I J H I j ^ l j l l j 201bp 
Fig. 3.20A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on SVCT2 and p-actin mRNA levels in the brain. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the brain was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and P-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); TV 二 3 for all 
experiments. 
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Fig. 3.21 Effects of administration of sulfur-containing amino acids and leucine 
for 14 days on GLUT3 and p-actin mRNA levels in the brain. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 days. Total 
RNA in the brain was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of GLUT3 to P-actin; N=?>. 
Gel data are shown in Fig. 3.21 A. 
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CTL Met Hey 
GLUT3 302 bp 
1 0.98 0.90 0.96 1.06 1.01 0.97 0.92 1.05 
p-actin 201bp 
CTL D-Cys L-Cys 
GLUT3 302 bp 
1 0.94 1.01 0.94 1 1.05 1.07 1.11 0.92 
CTL Tau Leu 
GLUT3 302 bp 
1 1.05 0.93 1.03 0.98 1.05 1.09 1.06 1 
mijmjjjjjjjji^jjjjmj^jmjujjj ^oibp 
Fig. 3.21A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on GLUT3 and p-actin mRNA levels in the brain. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the brain was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of GLUT3 and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PGR bands were indicated on the right (bp); N = 3 for all 
experiments. 
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Fig. 3.22 Effects of administration of sulfur-containing amino acids and leucine 
for 14 days on SVCT2 and p-actin mRNA levels in the brain. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 days. Total 
RNA in the brain was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of SVCT2 to p-actin; * p 
< 0.05 compared with the control. Gel data are shown in Fig. 3.22A. 
106 
* 
Chapter 3 Results 
CTL Met Hey 
M I I I I I I 
SVCT2 i ^ ^ m ^ m o o m o ^ m 504 bp 
1 0.93 1.02 0.87 0.91 1.08 0.92 0.91 0.98 
Metin ^ Q Q Q Q Q Q Q Q m 201bp 
CTL D-Cys L-Cys 
M I 1 厂 丨 丨 I 
SVCT2 j^j^ mm Q^om^mm 504 bp 
1 0.98 0.99 0.90 0.93 1.06 1.09 1 1 
P-actin ^oibp 
. CTL Tau Leu 
M I 1 I I I 1 
SVCT2 504 bp 
1 1.01 1 0.92 0.85 0.91 0.70 0.78 0.77 
l^ -actin H H m ^ H ^ ^ ^ O m ^ ^ ^ O m m 201bp 
Fig. 3.22A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCT2 and f-actin mRNA levels in the brain. Male 
B A L B / C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the brain was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); TV = 3 for all 
experiments. 
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Fig. 3.23 Effects of administration of methionine and homocysteine for 14 days 
on SVCTl and p-actin mRNA levels in the brain. Male BALB/c mice were 
treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), or saline (CTL) 
for 14 days. Total RNA in the brain was isolated and subjected to RT-PCR as 
described in Chapter 2. Expression of SVCTl and p-actin were measured and 
densitometry was used to quantify the density of bands. The DNA markers (M) 
were run on the same gel and sizes of the PGR bands were indicated on the right (bp); 
N= 3 for all experiments. 
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3.3.4. Effects of Sulfur-Containing Amino Acids and Leucine Administration 
on SVCT mRNA Expression in the Heart 
Experiments described in Section 3.2.5 demonstrated that administration of high 
concentrations of sulfur-containing amino acids and leucine for 7 and 14 days showed 
no significant change in ascorbic acid concentrations in the heart and this implies that 
ascorbic acid uptake was not altered. To ascertain this, SVCT mRNA levels were 
determined from total RNA isolates of the treated heart homogenates using RT-PCR. 
Results showed that there were no significant changes in SVCT2 mRNA levels after 
receiving sulfur-containing amino acids and leucine for either 7 or 14 days (Figs. 3.24 
& 3.25). This suggests that the ascorbic acid uptake was not altered, thus no 
significant change in ascorbic acid levels was observed. For SVCTl, no 
amplification product was detected in heart (Fig. 3.26) which is in agreement with the 
previous finding that heart is devoid of detectable SVCTl-specific transcript (Wang et 
al., 1999). 
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Fig. 3.24 Effects of administration of sulfur-containing amino acids and leucine 
for 7 days on SVCT2 and p-actin mRNA levels in the heart. Male BALB/c mice 
‘were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days. Total 
RNA in the heart was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of SVCT2 to P-actin; N=3>. 
Gel data are shown in Fig. 3.24A. 
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CTL Tau 
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Fig. 3.24A Effects of administration of sulfur-containing amino acids and 
leucine for 7 days on SVCT2 and p-actin mRNA levels in the heart. Male 
BALB/C mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hey), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 
days. Total RNA in the heart was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and P-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PCR bands were indicated on the right (bp); N = 3 for all 
experiments. 
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.Fig. 3.25 Effects of administration of sulfur-containing amino acids and leucine 
for 14 days on SVCT2 and p-actin mRNA levels in the heart. Male BALB/c 
mice were treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 days. Total 
RNA in the heart was isolated and subjected to RT-PCR as described in Chapter 2. 
Results were expressed as means 土 SEM of the ratios of SVCT2 to p-actin; N = 
Gel data are shown in Fig. 3.25A. 
112 
Chapter 3 Results 
CTL Met Hey 
SVCT2 504 bp 
1 0.98 0.86 1 0.97 0.99 1.03 1.07 0.98 
p-actin 謝匕卩 
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Fig. 3.25A Effects of administration of sulfur-containing amino acids and 
leucine for 14 days on SVCT2 and p-actin mRNA levels in the heart. Male 
BALB/c mice were treated with 100 mg/kg/d of methionine (Met), homocysteine 
(Hc'y), L- and D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 14 
days. Total RNA in the heart was isolated and subjected to RT-PCR as described in 
Chapter 2. Expression of SVCT2 and p-actin were measured and densitometry was 
used to quantify the density of bands. The DNA markers (M) were run on the same 
gel and sizes of the PGR bands were indicated on the right (bp); A^  = 3 for all 
experiments. 
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CTL D-Cys L-Cys 
P-actin 201bp 
Fig. 3.26 Effects of administration of cysteine for 14 days on SVCTl and 
p-actin mRNA levels in the heart. Male BALB/c mice were treated with 100 
mg/kg/d of L- and D-cysteine (Cys) or saline (CTL) for 14 days. Total RNA in the 
heart was isolated and subjected to RT-PCR as described in Chapter 2. Expression 
of SVCTl and p-actin were measured and densitometry was used to quantify the 
density of bands. The DNA markers (M) were run on the same gel and sizes of the 
PCR bands were indicated on the right (bp); 3 for all experiments. 
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3.3.5. Summary 
Results in Section 3.2 showed that administration of sulfur-containing amino acids 
and leucine altered ascorbic acid concentrations in the plasma and tissues, including 
the kidney, liver and brain. The ascorbic acid concentration was significantly 
decreased after receiving methionine, homocysteine, L-cysteine and leucine for 7 days 
both in the kidney and liver (see Sections 3.12 & 3.13). On the other hand, it can be 
seen that SVCT mRNA levels were declined after the above treatments (see Sections 
3.3.1 & 3.3.2). These results show that the decline in the sodium-dependent ascorbic 
acid transport gene after the treatments, may account for the lowering of tissues 
ascorbic acid content. 
In the brain, ascorbic acid concentration was increased significantly following the 
treatment with homocysteine and 丄-cysteine for 7 days (see Section 3.14). Using 
RT-PCR, an elevation in GLUT3 mRNA levels was observed (see Section 3.3.3). 
The above results suggest that a gain in GLUT-3 levels after receiving high 
concentrations of homocysteine and 丄-cysteine may be responsible for the increase in 
‘ascorbic acid concentrations in the brain. In contrast, a decrease in ascorbic acid 
concentration was found in the leucine group. As can be seen in Section 3.3.3, the 
mRNA levels of SVCT2 declined following the treatment of leucine, this suggest that 
the decrease in ascorbic acid levels in brain may due to the reduction of SVCT2 gene. 
In the heart, there were no significant changes in the ascorbic acid concentrations after 
receiving sulfur-containing amino acids and leucine for 7 and 14 days (see Section 
3.25). Therefore, we assumed that the ascorbic acid uptake was not altered. This 
assumption was in line with the lack of significant changes in SVCT2 mRNA levels 
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after treatments for 7 and 14 days (see Section 3.34). 
To conclude, i.p. administration of high concentration of sulfur-containing amino 
acids and leucine modifies ascorbic acid concentrations in plasma and tissues, and one 
of mechanisms involved is by altering the levels of SVCT and GLUT expression. 
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3.4. Sulfur-Containing Amino Acids Concentrations in the Plasma 
From Section 3.3, we observe that administration of sulfur-containing amino acids 
and leucine altered ascorbic acid concentrations in the plasma and tissues, including 
the kidney, liver and brain. In order to establish if there were any correlations 
between the levels of sulfur-containing amino acids, leucine and the changes of 
ascorbic acid status, mice were assigned to receive 100 mg/kg/d of methionine, 
homocysteine, L- and D-cysteine, taurine, leucine or saline (control) for 7 or 14 days, 
and the sulfur-containing amino acids and leucine concentrations in the plasma were 
determined using an amino acid analyzer according the method described in Section 
2.5. 
3.4.1. Effects of Administration of Sulfur-Containing Amino Acids and Leucine 
on Methionine Concentrations in the Plasma 
Fig. 3.27 showed the methionine concentration in the plasma after receiving 7 days 
and 14 days administration of sulfur-containing amino acids and leucine. No 
significant changes in the methionine levels were observed after receiving 
sulfur-containing amino acids for both 7 and 14 days. In contrast, the methionine 
concentrations were significantly decreased by 46 % {p < 0.05) and 51 % {p < 0.01) in 
the leucine group at days 7 and 14，respectively. 
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Fig. 3.27 Effects of administration of sulfur-containing amino acids and 
leucine on methionine concentrations in the plasma. Male BALB/c mice were 
treated with 100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and 
D-cysteine (Cys), taurine (Tau), leucine (Leu) or saline (CTL) for 7 days or 14 days. 
The methionine levels were assessed as described in Materials and Methods. 
Results were expressed as means 土 SEM; TV^ 二 6; * p < 0.05 compared with the 
corresponding control. 
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3.4.2. Effects of Administration of Sulfur-Containing Amino Acids and Leucine 
on Cystine Concentrations in the Plasma 
Upon standing at room temperature exposed to air at neutral pH, cysteine will oxidize 
to cystine, thus cystine instead of cysteine was measured in this study. Fig. 3.28 
demonstrated the cystine concentrations in the plasma after receiving 
sulfur-containing amino acids or leucine for 7 and 14 days. After receiving the 
above treatments for 7 days, no significant changes in cystine levels were observed. 
Following 14 days administration of methionine, homocysteine, I-cysteine and 
leucine, the cystine concentrations were significantly decreased by 20 % (p < 0.05), 
26 % (p < 0.01), 35 % (p < 0.005) and 35 % (p < 0.005), respectively, while no 
significant changes were observed after receiving D-cysteine and taurine. 
3.4.3. Effects of Administration of Sulfur-Containing Amino Acids and Leucine 
on Taurine Concentrations in the Plasma 
Fig. 3.29 showed the taurine concentrations in the plasma after administration of 
“sulfur-containing amino acids and leucine for 7 and 14 days. There were no 
significant changes in taurine concentrations after the above treatments. 
� 
119 
Chapter 3 Results 
U C T L S M e t 囲 Hey B L-Cys EDD-Cys El Tau BLeu 
140 
120 
丁 — 
云 100 r n r - " ， — r ~ i T 
I P “ � 1 
0 V >• >• * I 1 I 1 
S ^ S S ^ n : T ： ： ! ; 
1 I 騰 11 Ifeiii 
�_ _ i l . I t i i l 
limlii 
�LI ^mm 11 顧 I 
7 days 14 days 
Treatment period 
Fig. 3.28 Effects of administration of sulfur-containing amino acids and leucine 
on cystine concentrations in the plasma. Male BALB/c mice were treated with 
100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and D-cysteine (Cys), 
taurine (Tau), leucine (Leu) or saline (CTL) for 7 days or 14 days. The cystine 
levels were assessed as described in Materials and Methods. Results were expressed 
as means 土 SEM, TV = 6; * < 0.05 compared with the corresponding control. 
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Fig. 3.29 Effects of administration of sulfur-containing amino acids and leucine 
on taurine concentrations in the plasma. Male BALB/c mice were treated with 
100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and D-cysteine (Cys), 
taurine (Tau), leucine (Leu) or saline (CTL) for 7 days or 14 days. The taurine levels 
were assessed as described in Materials and Methods. Results were expressed as 
means 土 SEM, N=6. 
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3.4.4. Effects of Administration of Sulfur-Containing Amino Acids and Leucine 
on Leucine Concentrations in the Plasma 
Fig. 3.30 showed the leucine concentrations in the plasma after administration of 
sulfur-containing amino acids and leucine for 7 and 14 days. One week treatment 
with D-cysteine resulted in significantly {p < 0.05) lowering in leucine concentrations 
in the plasma, while no significant changes were observed with other treatments. 
Following 14 days injection, there were significant reductions in leucine 
concentrations in the homocysteine (-34 %), L-cysteine (- 40 %), D-Cysteine (- 35 %), 
and leucine (- 49 %) group. 
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‘Fig. 3.30 Effects of administration of sulfur-containing amino acids and leucine 
on leucine concentrations in the plasma. Male BALB/c mice were treated with 
100 mg/kg/d of methionine (Met), homocysteine (Hey), L- and D-cysteine (Cys), 
taurine (Tau), leucine (Leu) or saline (CTL) for 7 days or 14 days. The leucine 
levels were assessed as described in Materials and Methods. Results were expressed 
as means 土 SEM; N=6;* p< 0.05 compared with the control. 
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3.4.5. Summary 
In general, there were no significant changes in the levels of methionine, cystine, 
taurine and leucine after 7-day administration of sulfur-containing amino acids or 
leucine. Following 14 days administration, there was a significant decline in the 
cystine concentrations after receiving methionine, homocysteine, I-cysteine and 
leucine. Besides, the methionine concentration in the leucine group was lower than 
that in the control group. For leucine, a significant decrease was found after 
administration of homocysteine, cysteine and leucine. From the above, it can be 
seen that the changes in amino acid concentrations in the plasma exist in relatively 
longer treatment period. Besides, we cannot observe a clear correlation between the 
levels of sulfur-containing amino acids, leucine and the changes of ascorbic acid 
status in the plasma. 
Homocysteine is generated through the demethylation of methionine and largely 
catabolized by transsulfuration to cysteine or remethylated to methionine (see Fig 1.2). 
Our results showed that the effect of L-cysteine on the changes in the cystine status 
was similar to those of methionine and homocysteine, this may due to their close 
relationship in the metabolic pathway. In contrast, jD-cysteine showed no significant 
.changes in the cystine concentrations. One explanation is that D-cysteine is not 
involved in the methionine metabolism, unlike L-cysteine, which can be converted 
from methionine and homocysteine. 
Cysteine is the precursor for protein synthesis and several essential molecules, 
including, GSH, coenzyme A, taurine, and inorganic sulfur. Fig. 3.29 showed that 
after administration of cysteine, there was no change in the taurine concentration. 
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One possible explanation is that cysteine stimulates the formation of other essential 
molecules, rather than taurine. 
After administration of taurine, there were no significant changes in both methionine 
and cystine concentrations. It may due to the fact that taurine is the end metabolite 
of the methionine metabolism and it can not be converted back to cysteine or 
methionine. 
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CHAPTER 4 DISCUSSIONS AND CONCLUSIONS 
4.1. Effects of Sulfur-Containing Amino Acids and Leucine on Ascorbic Acid 
Concentrations in Mice 
Homocysteine is a natural occurring sulfur-containing amino acid; it is generated 
through the demethylation of methionine. These two and other sulfur-containing 
amino acids are closely related metabolically as shown in the ubiquitous methionine 
cycle (Fig. 1.2). In the liver, kidney, small intestine and pancreas, the 
transsulfuration pathway diverts homocysteine to cysteine and other essential 
molecules, such as taurine and GSH. Methionine metabolism is regulated by the 
disposition of homocysteine between the above competing sequences. 
The clinical significance of homocysteine is increasing day by day. Studies showed 
that hyperhomocysteinemia was associated with cardiovascular diseases (Cattaneo, 
1999; Refsum et al, 1998), renal diseases (Bostom et al., 1997; Dennis et al., 1996), 
and cognitive dysfunction including Alzheimer's disease (Clarke et al., 1998; 
Lehmann et al, 1999). Sulfur-containing amino acids are believed to be harmful to 
our health probably by inducing oxidative damage. On the other hand, ascorbic acid 
, is an important water-soluble antioxidant and plays an important role in maintaining 
health. It is essential for scavenging of superoxide and other reactive oxygen species 
and thus it is believed to offer protection against many diseases (Packer and Fuchs, 
1997; Retsky et al., 1993). 
To date, the relationship between the sulfur-containing amino acids and antioxidant 
vitamins in tissue remains obscured, it is of considerable interest to examine whether 
126 
Chapter 4 Discussions and Conclusions 
the oxidation caused by sulfur-containing amino acids decreases the levels of 
antioxidants, such as vitamin C, in our body. Therefore, the effects of 
sulfur-containing amino acids on vitamin C distribution in mice were investigated. 
Figs. 3.1 - 3.5 showed that 1-week administration of methionine, homocysteine and 
I-cysteine significantly decreased ascorbic acid concentrations in the plasma, kidney 
and liver. In the brain, the ascorbic acid concentration was significantly increased 
after receiving homocysteine, L-cysteine and taurine, while a significant decrease was 
observed in the methionine group. It can be seen that i.p. administration of high 
concentration of sulfur-containing amino acids modified the endogenous 
concentration of ascorbic acid in murine tissues. Besides, our results showed that 
the effect of I-cysteine was similar to those of methionine and homocysteine, this 
may due to^  their close relationship in the metabolic pathway. It is noted that 
sulfur-containing amino acids caused significant changes in ascorbic acid 
concentrations in the kidney, liver and brain, whereas no significant changes in 
ascorbic acid levels were found in the heart. This observation suggests that the 
modifications in ascorbic acid concentrations by sulfur-containing amino acids are 
tissue specific. This may due to the differences in the metabolic enzymes 
distribution among tissues. It is noted that CBS and cystathionine-y-lyase are absent 
. in the heart, but the brain contain CBS and the liver and kidney have both 
transsulfuration enzymes. Another explanation for the lack of effect is that the 
amino acids tested are not accumulated in the cardiac tissue, but this notion remains to 
be examined. 
In Section 1.3.3, it is noted that increased homocysteine and cysteine concentrations 
might accelerate coronary heart disease by various mechanisms, such as, promote the 
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generation of free radicals and hydrogen peroxide (Heinecke et al., 1987; Hogg, 1999; 
Starkebaum et al., 1986; Tsai et al., 1994; Welch et al., 1997) and support 
superoxide-mediated modification of LDL, which may facilitate foam cell formation 
(Heinecke et al., 1987; Parthasarathy, 1987). On the other hand, being an 
antioxidant, ascorbic acid readily scavenges nitrogen species and other reactive 
oxygen species, and offers protection against diseases (Packer and Fuchs, 1997; 
Retsky et al., 1993). In the present study, although no significant changes in 
ascorbic acid concentrations were found in the heart after treatment with 
sulfur-containing amino acids, the general trend of vitamin C concentrations was 
decreased. A decrease in vitamin C level may be associated with heart diseases 
caused by sulfur-containing amino acids, such as homocysteine and cysteine. It also 
suggests that vitamin C may not exert its beneficial effect in the heart directly. 
Vitamin C tpgether with other ways, such as, change in lifestyles and habits, may 
decrease the levels of sulfur-containing amino acids and protect against heart diseases 
more efficiently. 
Most amino acids important in nutrition have one asymmetric carbon atom and can 
exist in enantiomers. Only I-amino acids does enzyme-catalyzed polymerization 
build functional and structural peptides and proteins. D-amino acids are not utilized 
as protein building blocks. However, they exist in nature in both animals and plants 
(Berg, 1959; Friedman et al., 1981; Friedman et al., 1984; Meister, 1965). Since 
Z)-amino acids and L-amino acids derivatives are part of our diet, a need exists to 
access a better understanding in their roles. In this study, D-cysteine was included to 
determine whether stereospecifcity exists. Our results indicated that L- and 
D-cysteine had different effects on vitamin C distribution in mice (Figs. 3.1 - 3.5). 
丄-cysteine significantly increased ascorbic acid levels in the brain, while Z)-cysteine 
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did not. In the liver, the ascorbic acid concentration was significantly decreased 
after receiving 丄-cysteine, while no significant change was observed following 
jD-cysteine treatment. The reduction of ascorbic acid levels in I-cysteine group was 
greater than that in D-cysteine group in both plasma and kidney. These suggest that 
stereospecificity may exist. 
D-amino acids are utilized through the following two pathways: racemases or 
epimerases convert D-amino acid directly to L- or Dl-isomers; or via D-amino-acid 
oxidases to a- keto acids through oxidative deamination, which can then specifically 
be reaminated to the Z-form (Berg, 1959; Stegink, 1977). Since the biological 
utilization of D-amino acid is a complicated process; the amounts and specificities of 
D-amino-acid oxidase are varies in different animal species and in different tissues, 
and the less prominent, or lack of, effects observed with /^-cysteine may overload the 
oxidase system (Berg, 1959). Besides, Friedman and Gumbmann (1984) showed 
that //-cysteine had a sparing effect on L-methionine, but that D-cysteine did not. 
They suggested that D-cysteine may be nutritionally antagonistic and may impose a 
metabolic burden in the organism. Thus, the effects of D-cysteine on the changes in 
ascorbic acid status were smaller or even no significant change was observed when 
compare with L-cysteine which is a natural occurring amino acid. Another 
possibility may be related to the fact that D-cysteine was not transported into the cell 
efficiently to exert its effect. 
To determine if the changes in ascorbic acid levels are only limited to 
sulfur-containing amino acids, leucine, a non-sulfur containing amino acid, was 
examined. Leucine is chosen as a non-sulfur-containing amino acid control because 
it is an essential amino acid and must be obtained from the diet. The food sources of 
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leucine, including eggs, fish, lentils, poultry, beef, seeds and brown rice, are common 
foodstuffs that we usually come across. Besides, leucine is a relative stable amino 
acid as it is a branched chain amino acid (BCAA), which shows a unique tendency to 
escape hepatic uptake and/or metabolism after intestinal absorption (Miller, 1962), 
Results of the present study indicated that after 1 -week administration of leucine, the 
ascorbic acid concentrations decreased significantly in the kidney, liver and brain, 
while no significant changes were observed in the plasma and heart (Figs. 3.1 - 3.5). 
These suggest that leucine, though a non-sulfur-containing amino acid, can also affect 
the vitamin C distribution in mice and that changes in ascorbic acid status are not 
limited to sulfur-containing amino acids. 
In order to investigate the effects of the sulfur-containing amino acids and leucine on 
vitamin C levels in a relative shorter and longer period of time, mice were assigned to 
receive 100 mg/kg/d of methionine, homocysteine, L- and D-cysteine, taurine, leucine 
or saline as control group for 1 day or 14 days. The ascorbic acid concentrations in 
the plasma, kidney, liver, brain and heart were analyzed by HPLC. Our results 
showed that, in general, greater changes in ascorbic acid levels in the plasma and 
tissues, except the heart, were observed at day-7 when compared with day-1. A 
further decline in ascorbic acid levels were found at day-7 in the plasma, kidney and 
liver. In the brain, a significant increase in ascorbic concentrations was observed 
after 7 days administration of homocysteine, I-cysteine and taurine, while they 
showed no significant changes at day-1. Following 14 days treatment, the effect on 
the changes in ascorbic acid concentrations was smaller than that at day-7 or no 
significant change was observed. From Figs. 3.7 & 3.8，14 days treatment with 
sulfur-containing amino acids and leucine also resulted in a significant decrease in 
ascorbic acid levels in the kidney and liver, but the percentage of reduction was 
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smaller than those at day-7. Besides, there were no significant changes in ascorbic 
acid status after receiving sulfur-containing amino acids for 14 days in the plasma, 
brain and heart. Although the reasons for above phenomena are unknown, it may 
due to those mice be able to tolerate or mechanisms exist to maintain a steady 
ascorbic levels. The possible mechanisms that affect ascorbic acid status will be 
discussed later. It is noted that a significant decrease in ascorbic acid levels in the 
kidney and liver was observed after 1 day and 14 days treatment with 
sulfur-containing amino acids and leucine (Figs 3.7 & 3.8). These suggest that both 
sulfur-containing amino acids and leucine have significant effects on vitamin C levels 
in a relatively shorter and longer treatment period. 
4.2. Effects of Sulfur-Containing Amino Acids and Leucine on SVCT and 
GLUT3 Gene Expressions 
There are two mechanisms of vitamin C transport system: SVCT and GLUT in tissues. 
SVCTl is expressed in epithelial cells of kidney, intestine, and liver (Daruwala et al, 
1999; Faaland et al., 1998; Tsukaguchi et al., 1999) and SVCT2 has been detected 
mainly in brain and eyes (Rajan et al., 1999; Tsukaguchi et al., 1999). Results in 
Section 3.2 demonstrated that administration of 100 mg/kg/d of sulfur-containing 
amino acids and leucine altered ascorbic acid concentrations in the plasma and tissues, 
including the kidney, liver and brain. However, the mechanism remains unknown. 
Results presented in Sections 3.1.2 & 3.1.3 demonstrated that the ascorbic acid 
concentration was significantly decreased after receiving methionine, homocysteine, 
丄-cysteine and leucine for 7 days in both kidney and liver. At the same time, it can 
be seen that a reduction in both or one of the SVCT levels were observed after the 
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above treatments (Figs. 3.11, 3.12，3.15 & 3.16). These results show that the decline 
in the sodium-dependent ascorbic acid transport after the treatments may account for 
the loss in kidney and liver ascorbic acid content. 
In the brain, ascorbic acid concentration was increased significantly following 7 days 
administration of homocysteine and I-cysteine (see Section 3.1.4). An increase in 
GLUT3 mRNA levels was observed, while no significant changes in SVCT2 mRNA 
levels were found after the above treatments (Figs. 3.19 & 3.20) suggesting the more 
important role of GLUT3 in the brain. In normal brain, dehydroascorbic acid is not 
detectable. It appears after brain injury because vitamin C efficiently scavenges the 
reactive oxygen species and oxidized to dehydroascorbic acid (Castro et al., 2001). 
As discussed in Sections 1.3, high concentrations of homocysteine and cysteine can 
increase oxidative stress and cause neuronal injury. On the other hand, vitamin C 
can protect against brain injury by scavenging the reactive oxygen species and 
oxidized to dehydroascorbic acid (see Section 1.5). Fig. 3.19 showed that after 
receiving high concentrations of homocysteine and 丄-cysteine, the GLUT3 mRNA 
levels were increased significantly. As dehydroascorbic acid is taken up by GLUT3, 
an increase in GLUT3 levels may result in an increase in dehydroascorbic acid 
concentrations in the brain. Since high levels of dehydroascorbic acid might induce 
brain toxicity, it is recommended that brain cells take up dehydroascorbic acid and 
reduce to ascorbic acid to minimize its harmful effects (Patterson and Mastin, 1951; 
Rose et al, 1992). Hence, an increase in the ascorbic acid levels was observed. 
After 7 days administration of taurine, the ascorbic acid concentration was increased 
significantly, while no significant changes in ascorbate transporters, SVCT or GLUTS, 
were observed, in the brain. These suggest that the increased ascorbic acid 
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concentration by taurine in the brain is not related to the ascorbate transporters 
mechanisms. Studies showed that taurine exert neuroprotective effect against 
excitotoxic agents (French et al., 1986) and oxidative stress (Boldyrev et al., 1999). 
Our result indicated that administration of taurine for 7 days resulted in a significant 
increase in ascorbic acid concentration, this suggest that the beneficial effect of 
taurine in the brain may due to the increase in ascorbic acid levels. Although the 
mechanism involved is not known in the present study, this may due to taurine 
increases the vitamin C transport activity in the brain. 
In contrast, a decrease in ascorbic acid concentration was found in the leucine group 
at both day-7 and day-14. As can be seen in Figs. 3.20 & 3.22, the mRNA levels of 
SVCT2 declined following the treatment of leucine, these suggest that the decrease in 
ascorbic acid levels in brain may due to the reduction of SVCT2 mRNA levels. 
SVCT2 has been shown to be expressed mainly in the brain and retina (Rajan et al, 
1999; Tsukaguchi et al., 1999; Wang et al., 1999). 
In the present study, the whole brain was examined. In order to have a deeper 
understanding in the effects of sulfur-containing amino acids on the ascorbic acid 
distributions and its mechanisms involved in the brain, further studies should focus on 
the investigation in the ascorbic acid concentrations as well as the GLUTl and 
GLUT3 gene expressions in different brain regions. 
Fig. 3.10 demonstrated that administration of high concentrations of sulfur-containing 
amino acids and leucine for 7 days and 14 days showed no significant changes in 
ascorbic acid concentrations in the heart. Therefore, we assumed that ascorbic acid 
uptake was not altered. This assumption was in line with the lack of significant 
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changes in SVCT2 mRNA levels after treatments for 7 and 14 days (Figs. 3.24 & 
3.25). The lack of effect in the heart remains to be elucidated. Perhaps, a 
determination of amino acid profile in heart after amino acid administration may help 
to solve this mystery. 
Figs. 3.23 & 3.26 showed that no amplification product of SVCTl was observed in 
the brain and heart. These findings are in line with observations that the brain and 
heart are devoid of detectable SVCTl-specific transcript (Wang et al., 1999). 
In the present study, we focused on the expressions of genes of interest. Ideally, our 
results should be confirmed by measuring the SVCTl, SVCT2 and GLUT3 protein 
contents because transcription and translation may not be directly related. Therefore, 
it remains to be established whether the lower SVCT mRNA levels translate to lower 
protein contents. 
Furthermore, the mechanism behind the decline in SVCT was not explored in the 
present study. A decline in mRNA levels suggests either a decline in RNA stability 
or alterations in the regulation of SVCT transcription. The information about the 
transcriptional regulation of SVCTl and SVCT2 in the mice remains unclear, though 
limited information is available in human (Erichsen et al., 2001). These authors 
observed that due to the lack of sequence data on the 5'-untranslated regions of 
SVCTl and SVCT2, no specific transcription factors have been positively linked to 
changes in SVCT levels for any species. Therefore, it is worth to further study the 
transcriptional factors and binding motifs that may be involved in SVCT expression. 
This work will provide broader implications on the regulation of SVCT and a deeper 
understanding in the effect of sulfur-containing amino acids on ascorbic acid 
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distribution in various tissues. 
In Section 3.3, we observe that in some cases, the ascorbic acid levels was 
significantly decreased after treatment, however, no significant changes in SVCT 
mRNA levels were found. The reason remains to be established. This observation 
suggests that apart from altering the levels of ascorbate transporters, other potential 
mechanisms, for example oxidation, may exist for the lowering ascorbic acid levels 
observed. Moreover, it is interesting to note that de novo synthesis of ascorbic acid 
by gulonolactone oxidase (GLO) plays an important role in the maintenance of 
ascorbic aid levels in plasma and tissues of rodents (Nishikimi et al., 1996). Mice 
hapatocytes contain GLO and are thus capable of synthesizing ascorbic acid from 
glucose, a function lacking in human and other primates (Packer and Fuchs, 1997). 
It is possible that the decline in synthetic capacity can cause a differential loss of 
ascorbic acid after amino acid treatments. 
Recently, molecular mechanisms for ascorbic acid regenerating enzymes were 
„ reported. Reduction of dehydroascorbic acid is catalyzed by at least two 
NADPH-dependent enzymes, 3-a-hydroxysteroid dehydrogenase (HSD) (Del Bello et 
al., 1994) and thioredoxin reductase (TR) (May et al., 1997). On the other hand, 
ascorbic acid is regenerated from dehydroascorbic acid by the GSH-dependent 
enzymes, glutaredoxin (GRX) (Wells et al” 1990), protein disulphide-isomerase (PDI) 
(Wells et al.，1990), and GSH-dependent dehydroascorbic acid reductase (DAR) 
(Ishikawa et al., 1998; Maellaro et al., 1994). Once ascorbic acid reacts with 
radicals, it is oxidized to dehydroascorbic acid. Normally, dehydroascorbic acid is 
immediately reduced back to ascorbic acid by the above enzymes, including DAR, 
DRX, HSD, TRl: TR2, and PDI. As a result, one of the possible mechanisms for 
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ascorbic acid level declines is the decrease in the ascorbate recycling capacity in the 
liver. 
One more possible mechanism for ascorbic acid decline is the increase in utilization 
of ascorbic acid for antioxidant defense. In Section 1.3, we observe that high levels 
of sulfur-containing amino acids are risk factors of heart diseases, renal diseases, liver 
cirrhosis as well as Alzheimer's disease. They are harmful to our health by causing 
oxidation. Ascorbic acid is an important radical scavenger. Once it reacts with 
reactive oxygen and/or nitrogen species, it is oxidized to monodehydroascorbic acid, 
which is promptly oxidized further to dehydrosacorbic acid. 
Another possibility for the ascorbic acid level decline, particularly in the plasma, is 
the increase urinary excretion of ascorbic acid (Seghieri et al., 1994). Ascorbic acid 
is a water-soluble vitamin. It cannot be stored in our body, excessive vitamin C will 
be excreted in urine. Further study along this line may help to provide a clearer 
picture. 
Based on the above phenomenon, further studies should focus on the assay of mRNA, 
protein and activity of GLO as well as ascorbic acid regenerating enzymes, including 
DAR, GRX, PDI, TRl，TR2 and HSD in the liver. Besides, urinary levels of 
ascorbic acid and dehydroascorbic acid in the plasma and various tissues can be 
measured in order to obtain a more comprehensive evaluation of the relative 
contributions to the changes in the ascorbic acid status. To determine which 
mechanisms are the most important in ascorbic acid loss, a quantitative estimate of 
absorption, synthesis, and excretion are needed. 
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4.3. Sulfur-Containing Amino Acids Concentrations in the Plasma 
Results of the present study indicated that administration of sulfur-containing amino 
acids and leucine altered ascorbic acid concentrations in the plasma and tissues, 
including the kidney, liver and brain (Figs. 3.6 - 3.9). In order to establish if there 
were any correlations between the levels of sulfur-containing amino acids, leucine and 
the changes of ascorbic acid status, mice were assigned to receive 100 mg/kg/d of 
methionine, homocysteine, L- & D-cysteine, taurine, leucine or saline (control) for 7 
or 14 days and the sulfur-containing amino acids and leucine concentration in plasma 
was determined by amino acid analyzer. 
Results presented in Figs. 3.27 - 3.30 showed that in general there was no significant 
change in the levels of methionine, cystine, taurine and leucine after 7 days treatments. 
In Section 1.2.2, it is noted that methionine cycle and transsulfuartion pathway are 
well regulated by several mechanisms, including differences in the tissue content of 
metabolic enzymes, the inherent kinetic properties of the relevant enzymes and the 
regulation by oxidation/ reduction state. This can be one of the explanations that 
why no significant changes in sulfur-containing amino acids levels were observed in 
the plasma. Besides, after administration of amino acids, the liver responds by 
increasing its utilization of the non-BCAA. This results in rapid hepatic protein 
synthesis and formation of albumin. The excess amino acids are degraded and used 
in the synthesis of urea, with their carbon skeletons contributing to the formation of 
glucose and glycogen (Cherrington et al, 1987; Waldhausl et al., 1987) which provide 
energy for various biosynthetic processes. This rapid adaptation of the liver prevents 
the peripheral tissues from being exposed to excessive changes in free amino acid 
concentrations as a result of large intake of dietary amino acid (Munro et al” 1972). 
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In contrast to other amino acids, oxidation of the BCAA, e.g. leucine, occurs not in 
the liver (Miller, 1962), but primary in muscle (Buse et al., 1972; Goldberg et al., 
1972). 
Following 14 days administration, a significant decline in cystine concentration after 
receiving methionine, homocysteine,丄-cysteine and leucine was observed. Besides, 
the methionine concentration in the leucine group was lower than that in the control 
group. For leucine, a significant decrease was found after administration of 
homocysteine, cysteine and leucine. From the above, it can be seen that the changes 
in amino acid concentrations in the plasma exist in a relatively longer treatment 
period. One of the explanations for the reduction of amino acids in the general 
circulation may due to the decrease in proteolysis in the liver. The rapid adaptation 
of the liver Jhat prevents the peripheral tissues from being exposed to excessive 
changes in free amino acid concentrations may impair as a result of large intake of 
dietary amino acid for such long treatment period. 
Using the results obtained, we cannot observe a clear correlation between the levels of 
sulfur-containing amino acids, leucine and the changes of ascorbic acid status in the 
plasma. Further studies should focus on the determination of sulfur-containing 
, amino acid concentrations in tissues in order to obtain a clearer picture between them. 
Homocysteine is generated through the demethylation of methionine and largely 
catabolized by transsulfuration to cysteine or remethylated to methionine (see Fig 1.2). 
Our results showed that the effect of I-cysteine on the changes in the cystine status 
was similar to those of methionine and homocysteine, this may due to their close 
relationship in the metabolic pathway. In contrast, Z)-cysteine showed no significant 
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changes in the cystine concentrations. This may due to the fact that being a 
non-natural-occurring amino acid, the biological utilization of D-amino acid is a 
complicated process (Berg, 1959; Stegink, 1997) and D-cysteine was not transported 
into the cell efficiently to exert its effect. Another explanation is that /^-cysteine is 
not involved in the methionine metabolism, unlike I-cysteine, which can be converted 
from methionine and homocysteine. 
Cysteine formed from methionine and serine via transsulfuration and serves as a 
precursor for synthesis of essential molecules and protein. The essential molecules 
include GSH, coenzyme A, taurine and inorganic sulfate. Fig. 3.29 showed that 
after administration of cysteine, there was no change in the taurine concentration. 
One possible explanation is that cysteine stimulates the formation of other essential 
molecules, rather than taurine. 
After administration of taurine, there were no significant changes in both methionine 
and cystine concentrations. It may due to the fact that taurine is the end metabolite 
of the methionine metabolism and it can not be converted back to cysteine or 
methionine. 
. I n this study, plasma cystine instead of cysteine was measured because cysteine will 
oxidize to cystine upon standing at room temperature exposed to air at neutral pH 
(Malloy et al., 1981). In fact, cysteine and homocysteine have proven difficult to 
measure (Gaitonde, 1967) since the sulfhydryl form of these compounds fails to form 
a product with ninhydrin that gives an easily measurable color under conditions used 
in automatic amino acid analysis (Friedman et al., 1979). Therefore, no plasma 
homocysteine concentrations were found in this study. In further studies, we can use 
139 
Chapter 4 Discussions and Conclusions 
HPLC with fluorometric detection, which based on the reduction of protein-bound 
homocysteine, homocystine, and mixed disulfides to reduced homocysteine, followed 
by derivatization of the reduced homocysteine with thiol-specific fluorogenic reagents, 
or HPLC electrochemical detection to determine the homocysteine concentrations in 
the plasma. 
4.4. Conclusions 
The major finding of this study is the observation that i.p. administration of high 
concentration of sulfur-containing amino acids modified ascorbic acid concentrations 
in the plasma and tissues, including the kidney, liver and brain. Our results showed 
that 1 -week administration of methionine, homocysteine, L-cysteine significantly 
decreased ascorbic acid concentrations in the plasma, kidney and liver. In the brain, 
the ascorbic acid concentration was significantly increased after homocysteine, 
L-cysteine and taurine treatment, while a significant decrease was observed in the 
methionine group. In contrast, no significant changes were observed in the heart for 
all treatments. This observation suggests that the modifications in ascorbic acid 
levels by sulfur-containing amino acids are tissue specific. Besides, it can be seen 
that D- and L- cysteine had different effects on vitamin C distribution in mice. This 
indicates stereospecificity exists. Results of the present study indicated that after 
1 -week administration of leucine, the ascorbic acid concentrations decreased 
significantly in the kidney, liver and brain, while no significant changes were 
observed in the plasma and heart. These indicate that the effects on the changes in 
ascorbic acid status are not limited to sulfur-containing amino acids. Furthermore, a 
significant decrease in ascorbic acid status in the kidney and liver was observed after 
1 day and 14 days treatment with sulfur-containing amino acids and leucine. These 
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suggest that both sulfur-containing amino acids and leucine have significant effects on 
vitamin C levels in a relatively shorter and longer treatment period. 
In the present study, molecular studies indicated that the changes in ascorbic acid 
status are related to the changes in the levels of SVCT and GLUT3 gene expression in 
tissues. Our results demonstrated a good correlation between the reduction in 
ascorbic acid levels and SVCT mRNA levels after receiving methionine, 
homocysteine, I-cysteine and leucine for 7 days in both kidney and liver. Besides, a 
decrease in ascorbic acid concentration as well as SVCT2 mRNA levels was found in 
the brain of the leucine group. These results suggest that a decline in the 
sodium-dependent ascorbic acid transport account for the loss in tissues ascorbic acid 
content. 
In the brain, ascorbic acid concentration was increased significantly following 7-day 
administration of homocysteine and 丄-cysteine. In these animals, a gain in GLUT3 
mRNA levels was observed, but changes in SVCT2 mRNA levels were not found. 
The above results suggest that an increase in GLUT3 level may consequently lead to 
an increase in the brain ascorbic acid levels. 
Our results showed that the changes in amino acid concentrations in the plasma exist 
in a relatively longer treatment period and no clear correlation between the levels of 
sulfur-containing amino acids, leucine and the changes of ascorbic acid status is 
observed. 
Moderate elevation of total homocysteine concentration is an established independent 
risk factor for the development of vascular disease (Clarke et al., 1991). Such 
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elevation has also been associated with Alzheimer's disease (Clarke et al., 1998; 
Lehmann et al., 1999), renal diseases (Bostom et al., 1997; Dennis et al, 1996), as 
well as liver cirrhosis (Garcia-Trevijanos et al., 2001). Sulfur-containing amino 
acids are harmful to our health by inducing oxidative damage. On the other hand, 
ascorbic acid is an important antioxidant, which can scavenge of superoxide and other 
reactive oxygen species. It plays an important role in maintaining health. In the 
present study, we found that administration of high concentration of sulfur-containing 
amino acids modify ascorbic acid concentrations in the plasma and tissues, including 
the kidney, liver and brain. A significant decrease in the ascorbic acid levels were 
observed in the plasma, kidney and liver after receiving high concentration of 
methionine, homocysteine as well as cysteine. These suggest that the oxidation 
caused by high concentrations of sulfur-containing amino acid decrease the levels of 
vitamin C in our body. A high- protein food and drink may not be healthy as it may 
cause harmful effects to our health by lowering the levels of vitamin C and possibly 
other antioxidants. 
In summary, our results suggest that i.p. administration of high concentration of 
sulfur-containing amino acids modifies ascorbic acid concentrations in plasma and 
tissues, and one of the mechanisms involved is by altering the ascorbate transporters. 
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